Correctional Service Canada
Symbol of the Government of Canada

Common menu bar links

INFECTIOUS DISEASE SURVEILLANCE
in Canadian Federal Penitentiaries 2005-2006

Warning This Web page has been archived on the Web.

Previous page | ToC

 

Appendix A:
Human Immunodeficiency Virus (HIV)

Table A.1.i: HIV Screening Antibody Tests among ALL Inmates in Canadian
Federal Penitentiaries, IDSS† 2005-2006

Population Tested
Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)
1 – Number of new admissions (new warrants of committal) for the calendar year.
2 – Inmate population as of January 1st
3 – Flow through population (inmates in CSC January 1st plus all new admissions)

New Admissions1 576 572 1,062 966 1,389 1,389 1,351 1,564 508 588 4,819 5,079
Number of Tests Performed 309 324 498 467 762 934 733 841 116 79 2,418 2,645
Proportion of All New Admissions Receiving Test (%) (Testing Uptake) 53.6% 56.6% 46.9% 48.3% 54.9% 67.2% 54.3% 53.8% 22.8% 13.4% 50.2% 52.1%
Number of New Positive HIV Test Reports 1 1 1 2 3 2 1 2 1 0 7 7
New Positive HIV Test Reports as Proportion of Tests Performed (%) (test positivity) 0.09% 0.31% 0.20% 0.43% 0.39% 0.21% 0.14% 0.24% 0.86% 0.00% 0.29% 0.26%
General Population2 1,168 1,292 3,033 3,283 3,295 3,592 2,900 3,139 1,826 1,974 12,222 13,280
Number of Tests Performed 591 494 845 734 654 729 1,069 962 529 591 3,688 3,510
Proportion Of All General Population Inmates Receiving Test (%) (Testing Uptake) 50.6% 38.2% 27.9% 22.4% 19.8% 20.3% 36.9% 30.6% 29.0% 29.9% 30.2% 26.4%
Number of New Positive HIV Test Reports 1 0 1 2 1 0 2 3 2 3 7 8
New Positive HIV Test Reports as Proportion of Tests Performed (%) (Test Positivity) 0.17% 0.00% 0.12% 0.27% 0.15% 0.00% 0.19% 0.31% 0.38% 0.51% 0.19% 0.23%
Total3 1,744 1,864 4,095 4,249 4,684 4,981 4,251 4,703 2,334 2,562 17,041 18,359
Number of Tests Performed 900 818 1,343 1,201 1,416 1,663 1,802 1,803 645 670 6,106 6,155
Proportion of All Inmates Receiving Test (%) (Testing Uptake) 44.9% 43.9% 32.8% 28.3% 30.2% 33.4% 42.4% 38.3% 27.6% 26.2% 35.8% 33.5%
Number of New Positive HIV Test Reports 2 1 2 4 4 2 3 5 3 3 14 15
New Positive HIV Test Reports as Proportion of All Tests Performed (%) (Test Positivity) 0.22% 0.12% 0.15% 0.33% 0.28% 0.12% 0.17% 0.28% 0.47% 0.45% 0.23% 0.24%

 

Table A.1.ii: HIV Screening Antibody Tests among FEMALE Inmates in
Canadian Federal Penitentiaries, IDSS† 2005-2006

Population Tested
Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)
1 – Number of female new admissions (new warrants of committal) for the calendar year.
2 – Female Inmate population as of January 1st
3 – Flow through population (inmates in CSC January 1st plus all new admissions)

New Admissions1 42 39 35 39 74 90 99 95 20 40 270 303
Number of Tests Performed 23 24 31 44 113 100 79 127 5 18 251 313
Proportion of All New Admissions Receiving Test (%) (Testing Uptake) 54.8% 61.5% 88.6% 112.8% 152.7% 111.1% 79.8% 133.7% 25.0% 45.0% 93.0% 103.3%
Number of New Positive HIV Test Reports 0 0 1 2 1 0 1 0 0 0 3 2
New Positive HIV Test Reports as Proportion of Tests Performed (%) (Test Positivity) 0.00% 0.00% 3.23% 4.55% 0.88% 0.00% 1.27% 0.00% 0.00% 0.00% 1.20% 0.64%
General Population2 40 60 70 82 104 104 126 146 47 53 387 445
Number of Tests Performed 21 46 10 10 5 8 79 94 30 30 145 188
Proportion of All General Population Inmates Receiving Test (%) (Testing Uptake) 52.5% 76.7% 14.3% 12.2% 4.8% 7.7% 62.7% 64.4% 63.8% 56.6% 37.5% 42.2%
Number of New Positive HIV Test Reports 0 0 0 0 0 0 0 0 0 0 0 0
New Positive HIV Test Reports as Proportion of Tests Performed (%) (Test Positivity) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Total3 82 99 105 121 178 194 225 241 67 93 657 748
Number of Tests Performed 44 70 41 54 118 108 158 221 35 48 396 501
Proportion of All Inmates Receiving Test (%) (Testing Uptake) 53.7% 70.7% 39.0% 44.6% 66.3% 55.7% 70.2% 91.7% 52.2% 51.6% 60.3% 67.0%
Number of New Positive HIV Test Reports 0 0 1 2 1 0 1 0 0 0 3 2
New Positive HIV Test Reports as Proportion of All Tests Performed (%) (Test Positivity) 0.00% 0.00% 2.44% 3.70% 0.85% 0.00% 0.63% 0.00% 0.00% 0.00% 0.76% 0.40%



Table A.1.iii: HIV Screening Antibody Tests among MALE Inmates in
Canadian Federal Penitentiaries, IDSS† 2005-006


Population Tested
Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)
1 – Number of male new admissions (new warrants of committal) for the calendar year.
2 – Male Inmate population as of January 1st
3 – Flow through population (inmates in CSC January 1st plus all new admissions)

New Admissions1 534 533 1,027 927 1,248 1,299 1,252 1,469 488 548 4,549 4,776
Number of Tests Performed 286 300 467 423 649 834 654 714 111 61 2,167 2,332
Proportion of All New Admissions Receiving Test (%) (Testing Uptake) 53.6% 56.3% 45.5% 45.6% 52.0% 64.2% 52.2% 48.6% 22.7% 11.1% 47.6% 48.8%
Number of New Positive HIV Test Reports 1 1 0 0 2 2 0 2 1 0 4 5
New Positive HIV Test Reports as Proportion of Tests Performed (%) (Test Positivity) 0.35% 0.33% 0.00% 0.00% 0.31% 0.24% 0.00% 0.28% 0.90% 0.00% 0.18% 0.21%
General Population2 1,128 1,232 2,963 3,201 3,191 3,488 2,774 2,993 1,779 1,921 11,835 12,835
Number of Tests Performed 570 448 835 724 649 721 990 868 499 561 3,543 3,322
Proportion of All General Population Inmates Receiving Test (%) (Testing Uptake) 50.5% 36.4% 28.2% 22.6% 20.3% 20.7% 35.7% 29.0% 28.0% 29.2% 29.9% 25.9%
Number of New Positive HIV Test Reports 1 0 1 2 1 0 2 3 2 3 7 8
New Positive HIV Test Reports as Proportion of Tests Performed (%) (Test Positivity) 0.18% 0.00% 0.12% 0.28% 0.15% 0.00% 0.20% 0.35% 0.40% 0.53% 0.20% 0.24%
Total3 1,662 1,765 3,990 4,128 4,439 4,787 4,026 4,462 2,267 2,469 16,384 17,611
Number of Tests Performed 856 748 1,302 1,147 1,298 1,555 1,644 1,582 610 622 5,710 5,654
Proportion of All Inmates Receiving Test (%) (Testing Uptake) 51.5% 42.4% 32.6% 27.8% 29.2% 32.5% 40.8% 35.5% 26.9% 25.2% 34.9% 32.1%
Number of New Positive HIV Test Reports 2 1 1 2 3 2 2 5 3 3 11 13
New Positive HIV Test Reports as Proportion of All Tests Performed (%) (Test Positivity) 0.23% 0.13 0.08% 0.17% 0.23% 0.13% 0.12% 0.32% 0.49% 0.48% 0.19% 0.23%

 

Table A.2: Cumulative Number of HIV Cases and HIV Prevalence in
Canadian Federal Penitentiaries, IDSS† 2005 – 2006.

  Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)

Number of New Admissions Newly HIV-Positive 1 1 1 2 3 2 1 2 1 0 7 7
Number of New Admissions Already Known to be HIV Positive 13 7 59 64 16 17 28 36 10 31 126 155
Number of HIV Infections Amongst New Admissions 14 8 60 66 19 19 29 38 11 31 133 162
HIV Prevalence Rate Among New Admissions 2.43% 1.40% 5.65% 6.83% 1.44% 1.37% 2.15% 2.43% 2.17% 5.27% 2.76% 3.19%
Number of New HIV Diagnosis Amongst General Population Inmates 1 0 1 2 1 0 2 3 2 3 7 8
Number of Deaths of HIV-Positive Inmates 2 0 4 1 1 0 0 4 2 1 9 6
Number of HIV-Positive Inmates Released to the Community 16 10 71 64 19 23 28 39 41 57 175 193
Reported Number of HIV Positive Inmates at Year-End 15 16 53 56 40 51 45 50 51 45 204 218
Males 13 13 53 53 38 48 38 40 51 44 193 198
Females 2 3 0 3 2 3 7 10 0 1 11 20
Overall HIV prevalence 1.28% 1.24% 1.75% 1.71% 1.21% 1.42% 1.55% 1.59% 2.79% 2.28% 1.67% 1.64%
Males 1.15% 1.06% 1.79% 1.66% 1.19% 1.38% 1.37% 1.34% 2.87% 2..29% 1.63% 1.54%
Females 5.00% 5.00% 0.00% 3.66% 1.92% 2.88% 5.56% 6.85% 0.00% 1.89% 2.84% 4.49%

 

Table A.3: Treatment of HIV-Positive Inmates in Canadian Federal Penitentiaries, IDSS† 2005 - 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)

Total Number of Inmates Initiated on HIV Therapy 1 2 15 12 6 6 14 15 14 35 50 70
Males 0 0 13 7 6 5 10 13 14 34 43 59
Females 1 2 2 5 0 1 4 2 0 1 7 11
Average Monthly Number of HIV Positive Inmates per Month 12.6 15 64.7 61 36.9 46 41.8 46 46.8 47 203 215
Males 10.5 13 61.8 58 34.8 44 34.2 38 46.8 47 188 199
Females 2.1 3 2.8 3 2.1 2 7.7 8 0.0 1 15 16
Average Monthly Number of HIV Positive Inmates Receiving Antiretroviral Treatment 6.7 5 42.0 40 23.5 27 22.1 28 15.6 17 110 114
Males 5.9 5 40.5 38 23.5 26 18.4 22 15.6 16 104 107
Females 0.8 0 1.5 2 0.0 1 3.7 3 0.0 0 6 7
Average Monthly Proportion of Reported HIV-Positive Inmates
Receiving Antiretroviral Treatment (%) (Treatment Uptake)
53.0% 32.0% 64.9% 65.5% 63.7% 59.5% 52.8% 54.4% 33.3% 35.0% 54.2% 52.9%
Males 56.3% 37.1% 65.5% 65.9% 67.5% 60.0% 53.9% 57.2% 33.3% 34.7% 55.3% 53.8%
Females 36.0% 6.7% 52.9% 59.5% 0.0% 50.0% 47.8% 41.1% 0.0% 66.7% 40.3% 41.3%

 

Table A.4.i: HIV Screening and Testing among NEW ADMISSIONS by REGION and GENDER, Web-IDSS† 2005 – 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1a – includes 41 Region unknown (38 males and 3 females);
1b - includes 16 gender unknown
2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown
3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown
4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HIV data results)
5 – total number of HIV cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested

Number of New Admissions 410 51 948 45 2,229 1 1,474 174 417 34 5,516 308 5,840
HIV History
Previous HIV Test 193 37 553 32 963 0 883 132 310 25 2,931 229 3,167
Previous HIV Test – Proportion 47.1% 72.5% 58.3% 71.1% 43.2% 0.0% 59.9% 75.9% 74.3% 73.5% 53.1% 74.4% 54.2%
Previous HIV + 3 0 4 2 19 0 9 8 5 0 40 10 50
Previous HIV + Proportion 1.6% 0.0% 0.7% 6.3% 2.0% – 1.0% 6.1% 1.6% 0.0% 1.4% 4.4% 1.6%
Previous HIV + Treated 0 0 1 1 5 0 3 2 1 0 10 3 13
Previous HIV + Treated Proportion 0.0% – 25.0% 50.0% 26.3% – 33.3% 25.0% 20.0% – 25.0% 30.0% 26.0%
HIV Screening on Admission
HIV Screening Test on Admission 402 49 916 43 1,455 1 1,339 156 332 29 4,477 281 4,770
Newly HIV Positive on Admission 2 0 1 0 0 0 4 1 2 0 9 1 10
HIV Screening Test Positivity Rate2 0.54% 0.0% 0.13% 0.0% 0.0% – 0.42% 1.03% 0.73% 0.0% 0.30% 0.51% 0.31%
Diagnostic Yield2 (newly diagnosed
per 1000 tests)
 5.4 0.0 1.3 0.0 0.0 – 4.2 10.3 7.3 0.0 3.0 5.1 3.1
Confirmatory Testing
Confirmed HIV Positive on Admission3 1 0 2 2 3 0 3 4 1 0 10 6 16
HIV Prevalence on Admission4
Total Number HIV5 3 0 4 2 18 0 12 9 7 0 44 11 55
HIV Prevalence – TESTED 0.81% 0.00% 0.53% 5.41% 2.98% – 1.25% 8.91% 2.55% 0.00% 1.47% 5.47% 1.72%
HIV Prevalence – Population 0.73% 0.00% 0.42% 4.44% 0.81% 0.00% 0.81% 5.17% 1.68% 0.00% 0.80% 3.57% 0.94%

 

Table A.4.ii: HIV Screening and Testing among GENERAL POPULATION by REGION and GENDER, Web-IDSS† 2005 – 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1a – includes 34 Region unknown (34 males and 0 females);
1b – includes 7 gender unknown

2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown
3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown
4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HIV data results)
5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested

Number of General Population 389 24 646 12 928 2 997 97 598 39 3,592 174 3,773
HIV History
Previous HIV Test 270 18 429 3 429 0 682 56 485 22 2,321 99 2,422
Previous HIV Test – Proportion 69.4% 75.0% 66.4% 25.0% 46.2% 0.0% 68.4% 57.7% 81.1% 56.4% 64.6% 56.9% 64.2%
Previous HIV + 1 0 1 0 3 0 7 1 2 0 14 1 15
Previous HIV + Proportion 0.4% 0.0% 0.2% 0.0% 0.7% – 1.0% 1.8% 0.4% 0.0% 0.6% 1.0% 0.6%
Previous HIV + Treated 0 0 0 0 0 0 1 0 0 0 1 0 1
Previous HIV + Treated Proportion 0.0% – 0.0% – 0.0% – 14.3% 0.0% 0.0% – 7.1% 0.0% 6.7%
HIV Screening General Population
HIV Screening Test General Population 375 24 626 12 744 1 926 92 582 36 3,286 165 3,458
Newly HIV Positive General Population 0 0 1 0 1 0 2 1 2 0 6 1 7
HIV Screening Test Positivity Rate2 0.0% 0.0% 0.20% 0.0% 0.16% – 0.24% 1.23% 0.38% 0.0% 0.21% 0.66% 0.23%
Diagnostic Yield2 (newly diagnosed per 1000 tests) 0.0 0.0 2.0 0.0 1.6 – 2.4 12.3 3.8 0.0 2.1 6.6 2.3
Confirmatory Testing
Confirmed HIV Positive General Population3 0 0 0 0 3 0 5 1 0 0 8 1 9
HIV Prevalence4
Total Number HIV5 1 0 2 0 4 0 8 2 3 0 18 2 20
HIV Prevalence – TESTED 0.30% 0.00% 0.39% 0.00% 0.64% – 0.96% 2.44% 0.57% 0.00% 0.63% 1.31% 0.66%
HIV Prevalence – Population 0.26% 0.00% 0.31% 0.00% 0.43% 0.00% 0.80% 2.06% 0.50% 0.00% 0.50% 1.15% 0.53%

 

Table A.4.iii: OVERALL HIV Prevalence by REGION and GENDER, Web-IDSS† 2005 – 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1a – includes 58 Region unknown (56 males and 2 females);
1b – includes 23 gender unknown

2 – Proportion of those tested (for whom a laboratory result is recorded in Web-IDSS) who are laboratory confirmed positive
3 – Proportion of the entire population who are known to be HIV positive

Number of Inmates in Web-IDSS 748 65 1,477 50 2,863 2 2,247 224 938 59 8,329 402 8,754
HIV Testing and Results
HIV Tests 734 63 1,438 50 2,031 2 2,069 211 853 54 7,177 382 7,578
HIV Positive 3 0 4 0 17 0 17 7 8 0 49 7 56
HIV Prevalence – Tested2 0.44% 0.00% 0.33% 0.00% 1.41% 0.00% 1.01% 4.27% 1.05% 0.00% 0.88% 2.14% 0.95%
HIV Prevalence – Population3 0.40% 0.00% 0.27% 0.00% 0.59% 0.00% 0.76% 3.13% 0.85% 0.00% 0.59% 1.74% 0.64%

 

Table A.5.i: HIV Screening and Testing among NEW ADMISSIONS by ORIGIN, Web-IDSS† 2005 – 2006
  Canadian-born
 non-Aboriginal
Canadian-born Aboriginal Foreign-born Unknown CSC1
Number of New Admissions 3,355 1,007 602 876 5,840

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 – Total number of New Admissions in Web-IDSS by Origin
2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown
3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown
4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HIV data results)
5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested

HIV History
Previous HIV Test 1,722 671 219 555 3,167
Previous HIV Test – Proportion 51.3% 66.6% 36.4% 63.4% 54.2%
Previous HIV + 25 13 4 8 50
Previous HIV + Proportion 1.5% 1.9% 1.8% 1.4% 1.6%
Previous HIV + Treated 5 4 2 2 13
Previous HIV + Treated Proportion 20.0% 30.8% 50.0% 25.0% 26.0%
HIV Screening on Admission
HIV Screening Test on Admission 2,745 881 423 721 4,770
Newly HIV Positive on Admission 4 4 0 2 10
HIV Screening Test Positivity Rate2 0.22% 0.62% 0.0% 0.41% 0.31%
Diagnostic Yield2 (newly diagnosed per 1000 tests) 2.2 6.2 0.0 4.1 3.1
Confirmatory Testing
Confirmed HIV Positive on Admission3 7 5 1 3 16
HIV Prevalence on Admission4
Total Number HIV5 25 16 4 10 55
HIV Prevalence – TESTED 1.36% 2.45% 1.83% 2.04% 1.72%
HIV Prevalence – Population 0.75% 1.59% 0.66% 1.14% 0.94%

 

Table A.5.ii: HIV Screening and Testing among GENERAL POPULATION by
ORIGIN, Web-IDSS† 2005 – 2006
  Canadian-born
non-Aboriginal
Canadian-born 
Aboriginal
Foreign-born Unknown CSC1
Number of general population 1,801 836 260 876 3,773

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 –total number of General Population (including temporary detainees) in Web-IDSS by Origin
2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown
3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown
4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HIV data results)
5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested

HIV History
Previous HIV Test 1,088 604 133 597 2,422
Previous HIV Test – Proportion 60.4% 72.2% 51.2% 68.2% 64.2%
Previous HIV + 6 7 0 2 15
Previous HIV + Proportion 0.6% 1.2% 0.0% 0.3% 0.6%
Previous HIV + Treated 0 1 0 0 1
Previous HIV + Treated Proportion 0.0% 14.3% – 0.0% 6.7%
HIV Screening General Population          
HIV Screening Test General Population 1,644 776 227 811 3,458
Newly HIV Positive General Population 3 1 0 3 7
HIV Screening Test Positivity Rate2 0.21% 0.15% 0.0% 0.44% 0.23%
Diagnostic Yield2 (newly diagnosed per 1000 tests) 2.1 1.5 0.0 4.4 2.3
Confirmatory Testing
Confirmed HIV Positive General Population3 1 6 0 2 9
HIV Prevalence4
Total Number HIV5 8 7 0 5 20
HIV Prevalence – TESTED 0.56% 1.01% 0.00% 0.73% 0.66%
HIV Prevalence – Population 0.44% 0.84% 0.00% 0.57% 0.53%

 

Table A.5.iii: OVERALL HIV Prevalence by ORIGIN, Web-IDSS† 2005 – 2006.
  Canadian-born
non-Aboriginal
Canadian-born Aboriginal Foreign-born Unknown CSC
Number of Inmates in Web-IDSS 4,679 1,652 801 1,622 8,754

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 – Proportion of those tested (for whom a laboratory result is recorded in Web-IDSS) who are laboratory confirmed positive
2 – Proportion of the entire population who are laboratory confirmed positive

HIV testing and results
HIV Tests 4,031 1,511 606 1,430 7,578
HIV Positive 26 16 3 11 56
HIV Prevalence – Tested1 0.83% 1.27% 0.75% 0.98% 0.95%
HIV Prevalence – Population2 0.56% 0.97% 0.37% 0.68% 0.64%

 

Appendix B:
Hepatitis C Virus (HCV)

Table B.1.i: HCV Screening Antibody Tests among ALL Inmates in
Canadian Federal Penitentiaries, IDSS† 2005-2006

Population Tested
Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)
1 – Number of new admissions (new warrants of committal) for the calendar year.
2 – Inmate population as of January 1st
3 – Flow through population (inmates in CSC January 1st plus all new admissions)

New Admissions1 576 572 1,062 966 1,322 1,389 1,351 1,564 508 588 4,819 5,079
Number of HCV Antibody Tests Performed 294 300 473 431 778 892 705 807 117 81 2,367 2,511
Proportion of All New Admissions Receiving Test (%) (Testing Uptake) 51.0% 52.4% 44.5% 44.6% 58.9% 64.2% 52.2% 51.6% 23.0% 13.8% 49.1% 49.4%
Number of New Positive HCV Test Reports 31 24 70 81 24 27 49 58 4 3 178 193
New Positive HCV Test Reports As Proportion of Tests Performed (%) (Test Positivity) 10.5% 8.0% 14.8% 18.8% 3.1% 3.0% 7.0% 7.2% 3.4% 3.7% 7.5% 7.7%
General Population2 1,168 1,292 3,033 3,283 3,295 3,592 2,900 3,139 1,826 1,974 12,222 13,280
Number of Tests Performed 528 429 721 646 592 651 908 826 373 446 3,122 2,998
Proportion of All General Population Inmates Receiving Test (%) (Testing Uptake) 45.2% 33.2% 23.8% 19.7% 18.0% 18.1% 31.3% 26.3% 20.4% 22.6% 25.5% 22.6%
Number of New Positive HCV Test Reports 48 52 15 22 31 33 52 33 30 24 176 164
New Positive HCV Test Reports as Proportion of Tests Performed (%) (Test Positivity) 9.1% 12.1% 2.1% 3.4% 5.2% 5.1% 5.7% 4.0% 8.0% 5.4% 5.6% 5.5%
Total3 1,744 1,864 4,095 4,249 4,617 4,981 4,251 4,703 2,334 2,562 17,041 18,359
Number of Tests Performed 822 729 1,194 1,077 1,370 1,543 1,613 1,633 490 527 5,489 5,509
Proportion of Inmates Receiving Test (%) (Testing Uptake) 47.1% 31.9% 29.2% 25.3% 29.7% 31.0% 37.9% 34.7% 21.0% 20.6% 32.2% 30.0%
Number of New Positive HCV Test Reports 79 76 85 103 55 60 101 91 34 27 354 357
New Positive HCV Test Reports as Proportion of All Tests Performed (%) (Test Positivity) 9.6% 10.4% 7.1% 9.6% 4.0% 3.9% 6.3% 5.6% 7.0% 5.1% 6.5% 6.5%


Table B.1:ii HCV Screening Antibody Tests among FEMALE Inmates in
Canadian Federal Penitentiaries, IDSS† 2005-2006

Population Tested
Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)
1 – Number of female new admissions (new warrants of committal) for the calendar year.
2 – Female Inmate population as of January 1st
3 – Flow through population (inmates in CSC January 1st plus all new admissions).

New Admissions1 42 39 35 39 74 90 99 95 20 40 270 303
Number of HCV Antibody Tests Performed 23 23 31 37 116 98 79 121 2 15 251 294
Proportion of All New Admissions Receiving Test (%) (Testing Uptake) 54.8% 59.0% 88.6% 94.9% 157% 109% 79.8% 127% 10.0% 37.5% 93.0% 97.0%
Number of New Positive HCV Test Reports 6 2 4 4 3 1 5 0 1 0 19 7
New Positive HCV Test Reports as Proportion of Tests Performed (%) (Test Positivity) 26.1% 8.7% 12.9% 10.8% 2.6% 1.0% 6.3% 0.0% 50.0% 0.0% 7.6% 2.4%
General Population2 40 60 70 82 104 104 126 146 47 53 387 445
Number of Tests Performed 19 33 9 3 7 15 44 50 14 14 93 115
Proportion of All General Population Inmates Receiving Test (%)(Testing Uptake) 47.5% 55.0% 12.9% 3.7% 6.7% 14.4% 34.9% 34.2% 29.8% 26.4% 24.0% 25.8%
Number of New Positive HCV Test Reports 0 3 0 0 0 0 2 0 2 0 4 3
New Positive HCV Test Reports as Proportion of Tests Performed (%) (Test Positivity) 0.0% 9.1% 0.0% 0.0% 0.0% 0.0% 4.6% 0.0% 14.3% 0.0% 4.3% 2.6%
Total3 82 99 105 121 178 194 225 241 67 93 657 748
Number of Tests Performed 42 56 40 40 123 113 123 171 16 29 344 409
Proportion of Inmates Receiving Test (%) (Testing Uptake) 51.2% 56.6% 38.1% 33.1% 69.1% 58.2% 54.7% 71% 23.9% 31.2% 52.4% 54.7%
Number of New Positive HCV Test Reports 6 5 4 4 3 1 7 0 3 0 23 10
New Positive HCV Test Reports as Proportion of All Tests Performed (%) (Test Positivity) 14.3% 8.9% 10.0% 10.0% 2.4% 0.9% 5.7% 0.0% 18.6% 0.0% 6.7% 2.4%

 

Table B.1.iii: HCV Screening Antibody Tests among MALE Inmates in
Canadian Federal Penitentiaries, IDSS† 2005-2006

Population Tested
Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)
1 – Number of male new admissions (new warrants of committal) for the calendar year.
2 – Male Inmate population as of January 1st
3 – Flow through population (inmates in CSC January 1st plus all new admissions)

New admissions1 534 533 1,027 927 1,248 1,299 1,252 1,469 488 548 4,549 4,776
Number of HCV Antibody Tests Performed 271 277 442 394 662 794 626 686 115 66 2,116 2,217
Proportion of All New Admissions Receiving Test (%) (Testing Uptake) 50.7% 52.0% 43.0% 42.5% 53.0% 61.1% 50.0% 46.7% 23.6% 12.0% 46.5% 46.4%
Number of New Positive HCV Test Reports 25 22 66 77 21 26 44 58 3 3 159 186
New Positive HCV Test Reports as Proportion of Tests Performed (%) (Test Positivity) 9.2% 7.9% 14.9% 19.5% 3.2% 3.3% 7.0% 8.5% 2.6% 4.6% 7.5% 8.4%
General Population2 1,128 1,232 2,963 3,201 3,191 3,488 2,774 2,993 1,779 1,921 11,835 12,835
Number of Tests Performed 509 396 712 643 585 636 864 776 359 432 3,029 2,883
Proportion of All General Population Inmates Receiving Test (%) (Testing Uptake) 45.1% 32.1% 24.0% 20.10% 18.3% 18.2% 31.1% 25.9% 20.2% 22.5% 25.6% 22.5%
Number of New Positive HCV Test Reports 48 49 15 22 31 33 50 33 28 24 172 161
New Positive HCV Test Reports as Proportion of Tests Performed (%) (Test Positivity) 9.4% 12.4% 2.1% 3.4% 5.3% 5.2% 5.8% 4.3% 7.8% 5.6% 5.7% 5.6%
Total3 1,662 1,765 3,990 4,128 4,439 4,787 4,026 4,462 2,267 2,469 16,384 17,611
Number of Tests Performed 780 673 1,154 1,037 1,247 1,430 1,490 1,462 474 498 5,145 5,100
Proportion of Inmates Receiving Test (%) (Testing Uptake) 46.9% 38.1% 28.9% 25.1% 28.1% 29.9% 37.0% 32.8% 20.9% 20.2% 31.4% 29.0%
Number of New Positive HCV Test Reports 73 71 81 99 52 59 94 91 31 27 331 347
New Positive HCV Test Reports as Proportion of All Tests Performed (%) (Test Positivity) 9.4% 10.6% 7.0% 9.6% 4.2% 4.1% 6.3% 6.2% 6.5% 5.4% 6.4% 6.8%

 

Table B.2: Cumulative Number of HCV Cases and HCV Prevalence in
Canadian Federal Penitentiaries, IDSS† 2005 – 2006.

  Atlantic Quebec Ontario Prairie Pacific CSC
Population Tested 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)

Number of New Admissions Newly HCV-Positive 31 24 70 81 24 27 49 58 4 3 178 193
Number of New Admissions Already Known to be HCV Positive 154 120 276 350 167 209 344 374 93 112 1,034 1,165
Number of HCV Infections Amongst New Admissions 185 144 346 431 191 236 393 432 97 115 1,212 1,358
HCV Prevalence Rate Among New Admissions 32.1% 25.2% 32.6% 44.6% 14.5% 17.0% 29.1% 27.6% 19.1% 19.6% 25.2% 26.7%
Number of New HCV Diagnosis Amongst General Population Inmates 48 52 15 22 31 33 52 33 30 24 176 164
Number of Deaths of HCV-Positive Inmates 1 0 6 1 2 3 2 5 7 3 18 12
Number of HCV-Positive Inmates Released to the Community 220 215 371 381 471 470 556 568 447 549 2,065 2,183
Reported Number of HCV Positive Inmates at Year-End. 361 450 542 634 970 924 886 878 822 775 3,581 3,661
Males 338 422 522 616 939 892 839 821 790 750 3,428 3,501
Females 23 28 20 18 31 32 47 57 32 25 153 160
Overall HCV Prevalence 30.9% 34.8% 17.9% 19.3% 29.4% 25.7% 30.6% 28.0% 45.0% 39.3% 29.3% 27.6%
Males 30.0% 34.3% 17.6% 19.2% 29.4% 25.6% 30.2% 27.4% 44.4% 37.0% 29.0% 27.3%
Females 57.5% 46.7% 28.6% 22.0% 29.8% 30.8% 37.3% 39.0% 68.1% 47.2% 39.5% 36.0%


Table B.3: Treatment of HCV-Positive Inmates in
Canadian Federal Penitentiaries, IDSS† 2005 - 2006.

  Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)

Total Number of Inmates Initiated on HCV Therapy 11 21 72 83 34 78 56 56 94 132 267 370
Males 11 16 64 75 34 70 53 52 89 122 251 335
Females 0 5 8 8 0 8 3 4 5 10 16 35
Average Monthly Number of HCV Positive Inmates per Month 342 413 561.6 588 950.5 943 864.4 862 853.1 816 3,572 3,621
Males 323 387 538.4 571 917.7 911 811.3 811 828.6 787 3,419 3,468
Females 20 25 23.2 17 32.8 32 53.1 51 24.5 29 153 154
Average Monthly Number of HCV Positive Inmates Receiving Antiviral Treatment 6.9 8 36.9 48 14.2 35 22.4 27 55.6 66 136 184
Males 6.0 6 34.8 44 13.4 30 20.8 27 52.1 62 127 169
Females 0.9 1 2.2 4 0.8 5 1.7 1 3.5 4 9 15

 

Table B.4.i: HCV Screening and Testing among NEW ADMISSIONS by REGION and GENDER, Web-IDSS† 2005 – 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1a – includes 41 Region unknown (38 males and 3 females);
1b - includes 16 gender unknown

2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown
3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown
4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HCV data results)
5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested

Number of New Admissions 410 51 948 45 2,229 1 1,474 174 417 34 5,516 308 5,840
HCV History
Previous HCV Test 180 35 498 29 905 0 785 110 278 22 2,675 199 2,880
Previous HCV Test – Proportion 43.9% 68.6% 52.5% 64.4% 40.6% 0.0% 53.3% 63.2% 66.7% 64.7% 48.5% 64.6% 49.3%
Previous HCV + 33 12 109 9 218 0 196 54 110 10 673 88 761
Previous HCV + Proportion 18.3% 34.3% 21.9% 31.0% 24.1% – 25.0% 49.1% 39.6% 45.5% 25.2% 44.2% 26.4%
Previous HCV + Treated 2 1 27 3 12 0 13 2 14 0 69 6 75
Previous HCV + Treated Proportion 6.1% 8.3% 24.8% 33.3% 5.5% – 6.6% 3.7% 12.7% 0.0% 10.3% 6.8% 9.9%
HCV Screening on Admission
HCV Screening Test on Admission 365 38 793 33 1,324 1 1,149 114 248 19 3,904 205 4,121
Newly HCV Positive on Admission 19 5 35 0 46 0 75 11 30 0 207 16 224
HCV Screening Test Positivity Rate2 6.1% 17.9% 5.9% 0.0% 9.3% – 10.0% 16.7% 16.5% 0.0% 8.8% 12.7% 9.0%
Diagnostic Yield2 (newly diagnosed
per 1000 tests)
61 179 59 0 93 – 100 167 165 0 88 127 90
Confirmatory Testing
Confirmed HCV Positive on Admission3 7 9 41 7 51 0 53 20 14 2 169 39 208
HCV Prevalence On Admission4
Total Number HCV5 48 17 143 9 259 0 264 64 138 10 858 103 962
HCV Prevalence – TESTED 14.8% 45.9% 22.4% 30.0% 46.8% – 32.5% 73.6% 69.7% 90.9% 33.6% 62.0% 35.3%
HCV Prevalence – Population 11.7% 33.3% 15.1% 20.0% 11.6% 0.0% 17.9% 36.8% 33.1% 29.4% 15.6% 33.4% 16.5%

 

Table B.4.ii: HCV Screening and Testing among GENERAL POPULATION by REGION and GENDER, Web-IDSS† 2005 – 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1a – includes 34 Region unknown (34 males and 0 females);
1b – includes 7 gender unknown

2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown
3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown
4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HCV data results)
5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested

Number of General Population 389 24 646 12 928 2 997 97 598 39 3,592 174 3,773
HCV History
Previous HCV Test 258 18 397 3 399 0 638 54 462 19 2,179 94 2,276
Previous HCV Test – Proportion 66.3% 75.0% 61.5% 25.0% 43.0% 0.0% 64.0% 55.7% 77.3% 48.7% 60.7% 54.0% 60.3%
Previous HCV + 45 5 95 1 82 0 175 23 154 11 555 40 596
Previous HCV + Proportion 17.4% 27.8% 23.9% 33.3% 20.6% – 27.4% 42.6% 33.3% 57.9% 25.5% 42.6% 26.2%
Previous HCV + Treated 3 0 20 1 5 0 17 1 37 1 83 3 86
Previous HCV + Treated Proportion 6.7% 0.0% 21.1% 100.0% 6.1% – 9.7% 4.3% 24.0% 9.1% 15.0% 7.5% 14.4%
HCV Screening General Population
HCV Screening Test General Population 335 17 519 10 688 1 744 67 406 28 2,721 123 2,850
Newly HCV Positive General Population 35 4 36 2 103 0 77 11 52 8 308 25 334
HCV Screening Test Positivity Rate2 12.3% 25.0% 9.5% 20.0% 18.7% 0.0% 12.6% 19.6% 15.6% 38.1% 14.1% 24.0% 14.6%
Diagnostic Yield2 (newly diagnosed per 1000 tests) 123 250 95 200 187 0 126 196 156 381 141 240 146
Confirmatory Testing
Confirmed HCV Positive General Population3 12 2 18 0 9 0 43 13 27 4 110 19 130
HCV Prevalence4
Total Number HCV5 81 8 127 3 185 0 249 36 201 20 851 67 920
HCV Prevalence – TESTED 27.5% 42.1% 31.7% 30.0% 33.0% 0.0% 38.0% 53.7% 55.1% 87.0% 37.0% 55.8% 37.9%
HCV Prevalence – Population 20.8% 33.3% 19.7% 25.0% 19.9% 0.0% 25.0% 37.1% 33.6% 51.3% 23.7% 38.5% 24.4%

 

Table B.4.iii: OVERALL HCV Prevalence by REGION and GENDER, Web-IDSS† 2005 – 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1a – includes 58 Region unknown (56 males and 2 females);
1b – includes 23 gender unknown

2 – Proportion of those tested (for whom a laboratory result is recorded in Web-IDSS) who are laboratory confirmed positive
3 – Proportion of the entire population who are laboratory confirmed positive

Number of Inmates in
Web-IDSS
748 65 1,477 50 2,863 2 2,247 224 938 59 8,329 402 8,754
HCV Testing and Results
HCV Tests 696 61 1,346 47 1,977 2 1,915 205 708 49 6,690 366 7,075
HCV Positive 113 16 228 5 360 0 437 64 310 25 1,458 111 1,572
HCV Prevalence – Tested2 18.9% 30.2% 22.7% 12.5% 32.8% 0.0% 31.1% 44.8% 56.7% 71.4% 31.1% 40.7% 31.6%
HCV Prevalence – Population3 15.1% 24.6% 15.4% 10.0% 12.6% 0.0% 19.4% 28.6% 33.0% 42.4% 17.5% 27.6% 18.0%

 

Table B.5.i: HCV Screening and Testing among NEW ADMISSIONS by ORIGIN, Web-IDSS† 2005 – 2006
  Canadian-born non-Aboriginal Canadian-born Aboriginal Foreign-born Unknown CSC1
Number of New Admissions 3,355 1,007 602 876 5,840

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 –total number of New Admissions in Web-IDSS by Origin
2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown
3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown
4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission (see section on Enhanced HCV data results)
5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested

HCV History
Previous HCV Test 1,564 607 185 524 2,880
Previous HCV Test – Proportion 46.6% 60.3% 30.7% 59.8% 49.3%
Previous HCV + 387 196 11 167 761
Previous HCV + Proportion 24.7% 32.3% 5.9% 31.9% 26.4%
Previous HCV + Treated 37 16 0 22 75
Previous HCV + Treated Proportion 9.6% 8.2% 0.0% 13.2% 9.9%
HCV Screening on Admission
HCV Screening Test on Admission 2,408 726 420 567 4,121
Newly HCV Positive on Admission 116 62 4 42 224
HCV Screening Test Positivity Rate2 7.9% 13.1% 2.0% 12.1% 9.0%
Diagnostic Yield2
(newly diagnosed per 1000 tests)
79 131 20 121 90
Confirmatory Testing
Confirmed HCV Positive on Admission3 117 58 1 32 208
HCV Prevalence On Admission4
Total Number HCV5 489 250 15 208 962
HCV Prevalence – TESTED 30.5% 46.3% 7.4% 54.6% 35.3%
HCV Prevalence – Population 14.6% 24.8% 2.5% 23.7% 16.5%

 

Table B.5.ii: HCV Screening and Testing among GENERAL POPULATION by ORIGIN,
Web-IDSS† 2005 – 2006

  Canadian-born Non-Aboriginal Canadian-born Aboriginal Foreign-born Unknown CSC1
Number of General Population 1,801 836 260 876 3,773

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 –total number of General Population (including temporary detainees) in Web-IDSS by Origin
2 – Based on denominator where a valid result is known (excludes tests where the result is missing) – data not shown
3 – Based on those who self-reported a previous positive on admission, who had a confirmatory test and who had a valid result (excludes tests where the result is missing) – data not shown
4 – Estimate is biased since the Web—IDSS data do not include all of the new admissions already positive on admission ((see section on Enhanced HCV data results)
5 – total number of cases: i) newly positive; ii) confirmed positive; or iii) self-reported positive but not tested

HCV History
Previous HCV Test 1,024 567 118 567 2,276
Previous HCV Test – Proportion 56.9% 67.8% 45.4% 64.7% 60.3%
Previous HCV + 245 176 10 165 596
Previous HCV + Proportion 23.9% 31.0% 8.5% 29.1% 26.2%
Previous HCV + Treated 33 23 3 27 86
Previous HCV + Treated Proportion 13.5% 13.1% 30.0% 16.4% 14.4%
HCV Screening General Population
HCV Screening Test General Population 1,405 608 212 625 2,850
Newly HCV Positive General Population 162 77 8 87 334
HCV Screening Test Positivity Rate2 14.3% 15.6% 4.4% 18.0% 14.6%
Diagnostic Yield2
(newly diagnosed per 1000 tests)
143 156 44 180 146
Confirmatory Testing
Confirmed HCV Positive General Population3 43 52 2 33 130
HCV Prevalence4
Total Number HCV5 402 251 18 249 920
HCV Prevalence – TESTED 34.0% 46.1% 9.9% 48.2% 37.9%
HCV Prevalence – Population 22.3% 30.0% 6.9% 28.4% 24.4%

 

Table B.5.iii: OVERALL HCV Prevalence by ORIGIN, Web-IDSS† 2005 – 2006.
  Canadian-born
Non-Aboriginal
Canadian-born Aboriginal Foreign-born Unknown CSC
Number of Inmates in
Web-IDSS
4,679 1,652 801 1,622 8,754

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 – Proportion of those tested (for whom a laboratory result is recorded in Web-IDSS)
who are laboratory confirmed positive

2 – Proportion of the entire population who are laboratory confirmed positive

HCV Testing and Results
HCV Tests 3,817 1,394 599 1,265 7,075
HCV Positive 736 409 29 398 1,572
HCV Prevalence – Tested1 27.4% 39.4% 7.7% 45.8% 31.6%
HCV Prevalence – Population2 15.7% 24.8% 3.6% 24.5% 18.0%

 

Appendix C:
Hepatitis A (HAV) and Hepatitis B (HBV) Virus

Table C.1: Hepatitis A and B Cases by REGION and GENDER, IDSS†, 2005 - 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)

Hepatitis A (HAV)
Acute HAV Cases (Women) 0 0 0 0 0 1 0 0 0 0 0 1
AcuteHAV Cases (Men) 0 0 0 0 0 0 0 0 0 0 0 0
Total Number of Acute
HAV Cases
0 0 0 0 0 1 0 0 0 0 0 1
Acute HAV Case Rate 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01%
Hepatitis B (HBV)
Acute HBV Cases (Women) 0 0 1 0 0 0 0 0 0 0 1 0
Acute HBV Cases (Men) 0 1 3 5 2 0 0 2 0 1 5 9
Total Number of Acute
HBV Cases
0 1 4 5 2 0 0 2 0 1 6 9
Acute HBV Case Rate 0.00% 0.08% 0.13% 0.15% 0.06% 0.00% 0.00% 0.06% 0.00% 0.05% 0.05% 0.07%

 

Table C.2.i: HAV Testing and Vaccination History, HAV Testing and Serology among
NEW ADMISSIONS by REGION and GENDER, Web-IDSS† 2005 – 2006.

  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS).
1a – includes 41 Region unknown (38 males and 3 females);
1b – includes 16 gender unknown

2 – Self-reported vaccination history
3 – Reactive for anti-HAV IgM, HAV IgG or total anti-HAV.

Number of New Admissions 410 51 948 45 2,229 1 1,474 174 417 34 5,516 308 5,840
Testing and HAV Vaccination History (Self Report)  
Previous HAV Test 104 10 196 23 840 0 477 68 138 18 1,766 122 1,892
Previous HAV Test Rate 25.4% 19.6% 20.7% 51.1% 37.7% 0.0% 32.4% 39.1% 33.1% 52.9% 32.0% 39.6% 32.4%
Previous HAV Positive 4 0 8 0 16 0 17 10 11 1 56 11 68
Previous HAV Positive Rate 3.8% 0.0% 4.1% 0.0% 1.9% – 3.6% 14.7% 8.0% 5.6% 3.2% 9.0% 3.6%
Previous HAV Positive Treatment 0 0 1 0 0 0 2 1 3 1 6 2 8
Previous HAV Positive Treatment Rate 0.0% – 12.5% – 0.0% – 11.8% 10.0% 27.3% 100.0% 10.7% 18.2% 11.8%
HAV Vaccination History2 139 7 452 21 182 0 306 42 173 16 1,269 89 1,359
HAV Vaccination History Rate 33.9% 13.7% 47.7% 46.7% 8.2% 0.0% 20.8% 24.1% 41.5% 47.1% 23.0% 28.9% 23.3%
HAV Testing and Serology among new admissions  
HAV Serological Tests 115 15 190 37 1,446 1 1,040 144 122 11 2,926 210 3,143
HAV Serological Tests Rate 28.0% 29.4% 20.0% 82.2% 64.9% 100.0% 70.6% 82.8% 29.3% 32.4% 53.0% 68.2% 53.8%
Number with Serological Immunity3 21 2 26 4 177 0 136 25 26 3 388 35 425
HAV Test Positivity 30.9% 25.0% 41.3% 30.8% 29.5% – 27.2% 32.9% 34.7% 100.0% 29.5% 34.7% 29.9%

 

Table C.2.ii: HAV Testing and Vaccination History, HAV Testing and Serology among GENERAL POPULATION by
RE GION and GENDER, Web-IDSS† 2005 – 2006.

  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS).
1a – includes 34 Region unknown (34 males and 0 females);
1b – includes 7 gender unknown

2 – Self-reported vaccination history
3 – Reactive for anti-HAV IgM, HAV IgG, or total anti-HAV.

Number of General Population 389 24 646 12 928 2 997 97 598 39 3,592 174 3,773
Testing and HAV Vaccination History
Previous HAV Test 112 8 167 0 274 0 397 32 194 9 1,163 49 1,213
Previous HAV Test Rate 28.8% 33.3% 25.9% 0.0% 29.5% 0.0% 39.8% 33.0% 32.4% 23.1% 32.4% 28.2% 32.1%
Previous HAV Positive 25 0 4 0 12 0 25 7 16 0 84 7 92
Previous HAV Positive Rate 22.3% 0.0% 2.4% – 4.4% – 6.3% 21.9% 8.2% 0.0% 7.2% 14.3% 7.6%
Previous HAV Positive Treatment 3 0 1 0 1 0 0 1 3 0 9 1 10
Previous HAV Positive Treatment Rate 12.0% – 25.0% – 8.3% – 0.0% 14.3% 18.8% – 10.7% 14.3% 10.9%
HAV Vaccination History2 168 4 314 2 134 0 418 21 296 13 1,344 40 1,386
HAV Vaccination History Rate 41.0% 16.7% 48.6% 16.7% 14.4% 0.0% 41.9% 21.6% 49.5% 33.3% 37.4% 23.0% 36.7%
HAV Testing and Serology among general population
HAV Serological Tests 265 6 229 6 624 1 446 52 153 16 1,731 81 1,818
HAV Serological Tests Rate 68.1% 25.0% 35.4% 50.0% 67.2% 50.0% 44.7% 53.6% 25.6% 41.0% 48.2% 46.6% 48.2%
Number with Serological Immunity3 128 1 36 0 171 0 88 9 34 9 459 19 481
HAV Test Positivity 62.1% 16.7% 39.6% 0.0% 36.6% 0.0% 33.6% 28.1% 45.9% 60.0% 41.6% 32.2% 41.2%

 

Table C.2.iii: HAV Testing and Vaccination History, HAV Testing and Serology among NEW ADMISSIONS by ORIGIN, Web-IDSS† 2005 – 2006.
  Canadian-born Aboriginal Foreign-born Unknown CSC1

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS).
1 – Total number of new admissions by Origin (including Unknown) in enhanced surveillance.
2 – Self-reported vaccination history
3 – Reactive for anti-HAV IgM, HAV IgG, or total anti-HAV.

Number of New Admissions 3,355 1,007 602 876 5,840
Testing and HAV Vaccination History (Self Report)
Previous HAV Test 1,030 393 149 320
1,892
Previous HAV Test Rate 30.7% 39.0% 24.8% 36.5% 32.4%
Previous HAV Positive 32 21 5 10 68
Previous HAV Positive Rate 3.1% 5.3% 3.4% 3.1% 3.6%
Previous HAV Positive Treatment 3 3 0 2 8
Previous HAV Positive Treatment Rate 9.4% 14.3% 0.0% 20.0% 11.8%
HAV Vaccination History2 781 279 70 229 1,359
HAV Vaccination History Rate 23.3% 27.7% 11.6% 26.1% 23.3%
HAV Testing and Serology on Admission
HAV Serological Tests 1,721 644 335 443 3,143
HAV Serological Tests Rate 51.3% 64.0% 55.6% 50.6% 53.8%
Number with Serological Immunity3 166 125 71 63 425
HAV Test Positivity 22.0% 38.3% 53.8% 30.4% 29.9%

 

Table C.2.iv: HAV Testing and Vaccination History, HAV Testing and Serology among
GENERAL POPULATION by ORIGIN, Web-IDSS† 2005 – 2006.

  Canadian-born Aboriginal Foreign-born Unknown CSC1

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS).
1 – Total number of new admissions by Origin (including Unknown) in enhanced surveillance.
2 – Web-IDSS did not have a results record for each test requisition.
3 – Reactive for anti-HAV IgM, HAV IgG, or total anti-HAV.

Number of General Population 1,801 836 260 876 3,773
Testing and HAV Vaccination History (Self Report)
Previous HAV Test 514 335 76 288 1,213
Previous HAV Test Rate 28.5% 40.1% 29.2% 32.9% 32.1%
Previous HAV Positive 32 27 10 23 92
Previous HAV Positive Rate 6.2% 8.1% 13.2% 8.0% 7.6%
Previous HAV Positive Treatment 7 2 0 1 10
Previous HAV Positive Treatment Rate 21.9% 7.4% 0.0% 4.3% 10.9%
HAV Vaccination History 661 346 66 313 1,386
HAV Vaccination History Rate 19.7% 41.4% 25.4% 35.7% 36.7%
HAV Testing and Serology as General Population
HAV Serological Tests 898 354 146 420 1,818
HAV Serological Tests Rate 49.9% 42.3% 56.2% 47.9% 48.2%
Number with Serological Immunity3 209 89 63 120 481
HAV Test Positivity 35.4% 43.8% 64.3% 43.5% 41.2%


Table C.3.i: HBV Testing and Vaccination History, HBV Testing and Serology among
NEW ADMISSIONS by REGION and GENDER, Web-IDSS† 2005 – 2006.

  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS).
1a – includes 41 Region unknown (38 males and 3 females);
1b – includes 16 gender unknown

2 – Self-reported vaccination history
3 –Reactive for total anti-HBc, anti-HBc IgM, anti-HBe, anti-HBs, HBeAg or HBsAg.

Number of New Admissions 410 51 948 45 2,229 1 1,474 174 417 34 5,516 308 5,840
Testing and HBV Vaccination History (Self Report)
Previous HBV Test 115 32 456 28 859 0 528 74 160 20 2,129 157 2,290
Previous HBV Test Rate 28.0% 62.7% 48.1% 62.2% 38.5% 0.0% 35.8% 42.5% 38.4% 58.8% 38.6% 51.0% 39.2%
Previous HBV Positive 5 1 20 0 30 0 22 12 20 0 98 13 112
Previous HBV Positive Rate 4.3% 3.1% 4.4% 0.0% 3.5% – 4.2% 16.2% 12.5% 0.0% 4.6% 8.3% 4.9%
Previous HBV Positive Treatment 0 0 7 0 1 0 1 1 1 0 10 1 11
Previous HBV Positive Treatment Rate 0.0% 0.0% 35.0% – 3.3% – 4.5% 8.3% 5.0% – 10.2% 7.7% 9.8%
HBV Vaccination History2 165 20 572 23 314 0 459 55 196 21 1,725 122 1,850
HBV Vaccination History Rate 40.2% 39.2% 60.3% 51.1% 14.1% 0.0% 31.1% 31.6% 47.0% 61.8% 31.3% 39.6% 31.7%
HBV Testing and Serology on Admission
HBV Serological Tests 123 48 824 40 1,429 1 1,096 141 127 13 3,619 245 3,873
HBV Serological Tests Rate 30.0% 94.1% 86.9% 88.9% 64.1% 100.0% 74.4% 81.0% 30.5% 38.2% 65.6% 79.5% 66.3%
Number with Serological Immunity3 14 6 373 17 248 0 174 24 38 2 852 50 904
HBV Test Positivity 15.6% 15.8% 54.5% 53.1% 40.5% – 26.9% 29.3% 49.4% 28.6% 40.1% 31.1% 39.4%

 

Table C.3.ii: HBV Testing and Vaccination History, HBV Testing and Serology among
GENERAL POPULATION by REGION and GENDER, Web-IDSS† 2005 – 2006.

  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS).
1a – includes 34 Region unknown (34 males and 0 females);
1b – includes 7 gender unknown

2 – Self-reported vaccination history
3 – Reactive for total anti-HBc, anti-HBc IgM, anti-HBe, anti-HBs, HBeAg or HBsAg.

Number of General Population 389 24 646 12 928 2 997 97 598 39 3,592 174 3,773
Testing and HBV Vaccination History
Previous HBV Test 129 18 301 1 284 0 481 36 191 9 1,405 64 1,471
Previous HBV Test Rate 33.2% 75.0% 46.6% 8.3% 30.6% 0.0% 48.2% 37.1% 31.9% 23.1% 39.1% 36.8% 39.0%
Previous HBV Positive 35 0 16 0 16 0 21 9 18 0 109 9 118
Previous HBV Positive Rate 27.1% 0.0% 5.3% 0.0% 5.6% – 4.4% 25.0% 9.4% 0.0% 7.8% 14.1% 8.0%
Previous HBV Positive Treatment 2 0 2 0 3 0 0 1 7 0 15 1 16
Previous HBV Positive Treatment Rate 5.7% – 12.5% – 18.8% – 0.0% 11.1% 38.9% – 13.8% 11.1% 13.6%
HBV Vaccination History 258 14 386 3 190 0 502 33 338 15 1,696 65 1,764
HBV Vaccination History Rate 66.3% 58.3% 59.8% 25.0% 20.5% 0.0% 50.4% 34.0% 56.5% 38.5% 47.2% 37.4% 46.8%
HAV Testing and Serology on General Population
HBV Serological Tests 260 23 381 10 593 1 533 52 152 19 1,941 105 2,053
HBV Serological Tests Rate 66.8% 95.8% 59.0% 83.3% 63.9% 50.0% 53.5% 53.6% 25.4% 48.7% 54.0% 60.3% 54.4%
Number with Serological Immunity3 157 6 183 6 217 0 124 13 36 12 728 37 767
HBV Test Positivity 71.0% 33.3% 59.6% 60.0% 44.9% 0.0% 31.8% 36.1% 42.9% 70.6% 48.6% 45.1% 48.3%

 

Table C.3.iii: HBV Testing and Vaccination History, HBV Testing and Serology among
NEW ADMISSIONS by ORIGIN, Web-IDSS† 2005 – 2006.

  Canadian-born Aboriginal Foreign-born Unknown CSC1

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS).
1 – Total number of new admissions by Origin (including Unknown) in enhanced surveillance.
2 – Self-reported vaccination history
3 – Reactive for total anti-HBc, anti-HBc IgM, anti-HBe, anti-HBs, HBeAg or HBsAg.

Number of New Admissions 3,355 1,007 602 876 5,840
Testing and Vaccination History (Self Report)
Previous HBV Test 1,287 434 168 401 2,290
Previous HBV Test Rate 38.4% 43.1% 27.9% 45.8% 39.2%
Previous HBV Positive 55 27 9 21 112
Previous HBV Positive Rate 4.3% 6.2% 5.4% 5.2% 4.9%
Previous HBV Positive Treatment 4 1 2 4 11
Previous HBV Positive Treatment Rate 7.3% 3.7% 22.2% 19.0% 9.8%
HBV Vaccination History2 1,039 367 90 354 1,850
HBV Vaccination History Rate 31.0% 36.4% 15.0% 40.4% 31.7%
HBV Testing and Serology on Admission
HBV Serological Tests 2,256 700 390 527 3,873
HBV Serological Tests Rate 67.2% 69.5% 64.8% 60.2% 66.3%
Number with Serological Immunity3 544 149 82 129 904
HBV Test Positivity 40.1% 33.5% 42.7% 43.1% 39.4%

 

Table C.3.iv: HBV Testing and Vaccination History, HBV Testing and Serology among
GENERAL POPULATION by ORIGIN, Web-IDSS† 2005 – 2006.

  Canadian-born Aboriginal Foreign-born Unknown CSC1

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS).
1 – Total number of new admissions by Origin (including Unknown) in enhanced surveillance.
2 – Web-IDSS did not have a results record for each test requisition.
3 – Reactive for total anti-HBc, anti-HBc IgM, anti-HBe, anti-HBs, HBeAg or HBsAg.

Number of General Population 1,801 836 260 876 3,773
Testing and Vaccination History (Self Report)
Previous HBV Test 641 375 84 371 1,471
Previous HBV Test Rate 35.6% 44.9% 32.3% 42.4% 39.0%
Previous HBV Positive 48 25 6 39 118
Previous HBV Positive Rate 7.5% 6.7% 7.1% 10.5% 8.0%
Previous HBV Positive Treatment 8 3 0 5 16
Previous HBV Positive Treatment Rate 16.7% 12.0% 0.0% 12.8% 13.6%
HBV Vaccination History2 831 416 82 435 1,764
HBV Vaccination History Rate 46.1% 49.8% 31.5% 49.7% 46.8%
HBV Testing and Serology as General Population
HBV Serological Tests 1,038 402 156 457 2,053
HBV Serological Tests Rate 57.6% 48.1% 60.0% 52.2% 54.4%
Number with Serological Immunity3 408 115 64 180 767
HBV Test Positivity 49.6% 39.5% 51.6% 51.4% 48.3%

 


Table C.4.i: Infectious HAV and HBV Cases and HBV Carriers by
REGION and GENDER, Web-IDSS† 2005 – 2006.

  Atlantic Quebec Ontario Prairie Pacific CSC

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS).
1 – Based on reactive serology result for anti-HAV IgM;
2 – Includes one HAV case Region unknown;
3 – Based on reactive serology result for anti-HBc IgM;
4 – Based on reactive serology result for anti-HBc IgM or HBsAg;
5 – Includes 2 Region unknown ( males=2 and females=0).

Acute (Active) HAV Cases1
Acute HAV Cases among New Admissions 1 2 0 7 2 12
Acute HAV cases (Men) 0 1 0 7 2 10
Acute HAV cases (Women) 1 1 0 0 0 2
Acute HAV Cases among General Population2 2 1 1 2 4 11
Acute HAV cases (Men) 2 1 1 2 4 10
Acute HAV cases (Women) 0 0 0 0 0 0
Total number of Acute HAV cases 3 3 1 9 6 23
Acute HBV Cases (Active Case)3
Acute HBV Cases among New Admissions 0 3 3 0 5 11
Acute HBV cases (Men) 0 3 3 0 5 11
Acute HBV cases (Women) 0 0 0 0 0 0
Acute HBV Cases among General Population 0 5 6 1 2 14
Acute HBV cases (Men) 0 5 6 1 2 14
Acute HBV cases (Women) 0 0 0 0 0 0
Total number of Acute HBV cases 0 8 9 1 7 25
All Infectious HBV Carriers (Cases)4
Acute HBV Carriers among New Admissions 1 7 10 12 16 46
HBV carriers (Men) 1 7 10 6 16 40
HBV carriers (Women) 0 0 0 6 0 6
Acute HBV Carriers among General Population5 7 8 16 17 4 54
HBV carriers (Men) 7 8 16 17 4 54
HBV carriers (Women) 0 0 0 0 0 0
Total number of Acute HBV carriers 8 15 26 29 20 100

 


Table C.4.ii: Infectious HAV and HBV Cases and HBV Carriers by ORIGIN,
Web-IDSS
† 2005 – 2006.

  Canadian-born Aboriginal Foreign-born Unknown CSC

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS).
1 – Based on reactive serology result for anti-HAV IgM.
2 – Based on reactive serology result for anti-HBc IgM.
3 – Based on reactive serology result for anti-HBc IgM or HBsAg.

Acute (Active) HAV Cases1
Acute HAV Cases (New Admissions) 4 3 1 4 12
Acute HAV Cases (General Population) 1 2 1 7 11
Total Acute HAV Cases 5 5 2 11 23
Acute HBV Cases (Active Case)2
Acute HBV Cases (New Admissions) 7 2 2 0 11
Acute HBV Cases (General Population) 6 2 1 5 14
Acute Total Acute HBV Cases 13 4 3 5 25
Infectious HBV Cases (Carrier)3
HBV Carriers (New Admissions) 21 11 12 2 46
HBV Carriers (General Population) 18 13 8 15 54
Total Acute HBV Carriers 39 24 20 17 100

 

Appendix D:
Sexually Transmitted Infections (STI)


Table D.1.i: Chlamydia Case Reports among Inmates in Canadian Federal Penitentiaries by
Gender and Region, IDSS†, 2005 - 2006.


Chlamydia
Atlantic Quebec Ontario Prairie Pacific CSC
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)

No. of Positive Test Reports 14 8 20 10 5 7 52 69 1 1 92 95
Male Cases 14 7 19 9 4 6 49 64 1 1 87 87
Male Prevalence Rate 1.24% 0.57% 0.64% 0.28% 0.13% 0.17% 1.77% 2.14% 0.06% 0.05% 0.74% 0.68%
Female Cases 0 1 1 1 1 1 3 5 0 0 5 8
Female Prevalence Rate 0.00% 1.67% 1.43% 1.22% 0.96% 0.96% 2.38% 3.42% 0.00% 0.00% 1.29% 1.8%
Overall Prevalence Rate 1.20% 0.62% 0.66% 0.30% 0.15% 0.19% 1.79% 2.20% 0.05% 0.05% 0.75% 0.72%

 


Table D.1.ii: Chlamydia History, Testing and Outcome by GENDER and REGION Web-IDSS† 2005 - 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
‡ -Numbers of new admissions / general population inmates in the enhanced surveillance system
1a – For New Admissions: includes 41 Region unknown (38 males and 3 females); For General Population: includes 34 Region unknown (34 males and 0 females)
1b – For New Admissions: includes 16 gender unknown; For General Population: includes 7 gender unknown

Number of New Admissions‡ 410 51 948 45 2,229 1 1,474 174 417 34 5,516 308 5,840
Previous chlamydia Test 59 23 265 25 125 0 435 86 67 11 959 147 1,107
Previous Test Uptake 14.4% 45.1% 28.0% 55.6% 5.6% 0.0% 29.5% 49.4% 16.1% 32.4% 17.4% 47.7% 19.0%
Previous Positive chlamydia 11 6 39 4 26 0 103 30 28 3 208 44 253
 Previous Test Positivity 18.6% 26.1% 14.7% 16.0% 20.8% – 23.7% 34.9% 41.8% 27.3% 21.7% 29.9% 22.9%
Previous chlamydia Treated 8 4 34 2 23 0 78 24 22 3 165 33 198
Proportion Treated 72.7% 66.7% 87.2% 50.0% 88.5% – 75.7% 80.0% 78.6% 100.0% 79.3% 75.0% 78.3%
Chlamydia Test on Admission 86 30 576 35 263 0 903 128 29 5 1,864 199 2,068
Testing Uptake 21.0% 58.8% 60.8% 77.8% 11.8% 0.0% 61.3% 73.6% 7.0% 14.7% 33.8% 64.6% 35.4%
Positive on Admission 1 1 13 1 0 0 54 1 0 0 68 3 72
Test Positivity 1.6% 5.9% 3.0% 11.1% 0.0% – 8.0% 1.5% 0.0% 0.0% 5.7% 3.2% 5.5%
LIFETIME PREVALENCE Among New Admissions 2.9% 13.7% 5.5% 11.1% 1.2% 0.0% 10.7% 17.8% 6.7% 8.8% 5.0% 15.3% 5.6%
Number General Population‡ 389 24 646 12 928 2 997 97 598 39 3,592 174 3,773
Chlamydia Tests Among General Population 216 10 266 6 62 0 409 56 105 13 1,074 85 1,159
Chlamydia Testing Uptake 55.5% 41.7% 41.2% 50.0% 6.7% 0.0% 41.0% 57.7% 17.6% 33.3% 29.9% 48.9% 30.7%
Positive Result 3 0 4 0 1 0 19 1 2 1 29 2 31
Test Positivity 1.7% 0.0% 2.2% 0.0% 2.7% – 6.8% 2.1% 2.9% 12.5% 3.8% 3.0% 3.8%
Population Prevalence Estimate 0.8% 0.0% 0.6% 0.0% 0.1% 0.0% 1.9% 1.0% 0.3% 2.6% 0.8% 1.1% 0.8%

 


Table D.1.iii: Chlamydia History, Testing and Outcome by ORIGIN Web-IDSS† 2005 - 2006.
  Canadian Aboriginal Foreign-born Unknown Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
‡ -Numbers of new admissions / general population inmates in enhanced surveillance system

Number of New Admissions‡ 3,355 1,007 602 876 5,840
Previous chlamydia Test 567 311 68 161 1,107
Previous Test Uptake 16.9% 30.9% 11.3% 18.4% 19.0%
Previous Positive chlamydia 117 87 15 34 253
Previous Test Positivity 20.6% 28.0% 22.1% 21.1% 22.9%
Previous chlamydia Treated 93 70 13 22 198
Proportion Treated 79.5% 80.5% 86.7% 64.7% 78.3%
Chlamydia Test on Admission 1,107 526 137 298 2,068
Testing Uptake 33.0% 52.2% 22.8% 34.0% 35.4%
Positive On Admission 30 26 2 14 72
Test Positivity 4.5% 6.9% 3.2% 7.3% 5.5%
Lifetime Prevalence 4.4% 11.2% 2.8% 5.5% 5.6%
Number General Population‡ 1,801 836 260 876 3,773
Chlamydia Tests Among General Population 508 322 61 268 1,159
Chlamydia testing uptake 28.2% 38.5% 23.5% 30.6% 30.7%
Positive result 11 14 2 4 31
Test positivity 3.1% 6.0% 4.7% 2.1% 3.8%
Population prevalence estimate 0.6% 1.7% 0.8% 0.5% 0.8%

 


Table D.2.i: Gonorrhea Case Reports among Inmates in Canadian Federal Penitentiaries by
GENDER and REGION, IDSS† 2005 - 2006.


Gonorrhea
Atlantic Quebec Ontario Prairie Pacific Canada
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)

No. of Positive Test Reports 0 0 0 3 0 2 11 15 0 0 11 20
Male Cases 0 0 0 3 0 1 10 15 0 0 10 19
Male Prevalence Rate 0.00% 0.00% 0.00% 0.09% 0.00% 0.03% 0.36% 0.50% 0.00% 0.00% 0.08% 0.15%
Female Cases 0 0 0 0 0 1 1 0 0 0 1 1
Female Prevalence Rate 0.00% 0.00% 0.00% 0.00% 0.00% 0.96% 0.79% 0.00% 0.00% 0.00% 0.26% 0.22%
Overall Prevalence Rate 0.00% 0.00% 0.00% 0.09% 0.00% 0.06% 0.38% 0.48% 0.00% 0.00% 0.09% 0.15%

 


Table D.2.ii: Gonorrhea History, Testing and Outcome by GENDER and REGION Web-IDSS† 2005 - 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
‡ -Numbers of new admissions / general population inmates in the enhanced surveillance system
1a – For New Admissions: includes 41 Region unknown (38 males and 3 females); For General Population: includes 34 Region unknown (34 males and 0 females)
1b – For New Admissions: includes 16 gender unknown; For General Population: includes 7 gender unknown

Number of new admissions‡ 410 51 948 45 2,229 1 1,474 174 417 34 5,516 308 5,840
Previous gonorrhea Test 49 23 258 24 122 0 390 80 55 11 880 140 1,020
Previous Test Uptake 12.0% 45.1% 27.2% 53.3% 5.5% 0.0% 26.5% 46.0% 13.2% 32.4% 16.0% 45.5% 17.5%
Previous Positive gonorrhea 3 1 22 4 18 0 45 15 17 0 106 21 127
Previous Test Positivity 6.1% 4.3% 8.5% 16.7% 14.8% – 11.5% 18.8% 30.9% 0.0% 12.0% 15.0% 12.5%
Previous gonorrhea Treated 2 0 18 4 17 0 37 9 13 0 88 13 101
Proportion Treated 66.7% 0.0% 81.8% 100.0% 94.4% – 82.2% 60.0% 76.5% – 83.0% 61.9% 79.5%
Gonorrhea Test on Admission 84 30 582 35 254 0 844 127 30 5 1,800 198 2,003
Testing Uptake 20.5% 58.8% 61.4% 77.8% 11.4% 0.0% 57.3% 73.0% 7.2% 14.7% 32.6% 64.3% 34.3%
Positive on Admission 0 0 0 1 0 0 9 1 0 0 9 2 11
Test Positivity 0.0% 0.0% 0.0% 12.5% 0.0% – 1.5% 1.5% 0.0% 0.0% 0.8% 2.1% 0.9%
LIFETIME PREVALENCE 0.7% 2.0% 2.3% 11.1% 0.8% 0.0% 3.7% 9.2% 4.1% 0.0% 2.1% 7.5% 2.4%
Number General Population‡ 389 24 646 12 928 2 997 97 598 39 3,592 174 3,773
Gonorrhea Tests Among General Population 211 10 240 6 54 0 375 54 102 12 997 82 1,079
Gonorrhea Testing Uptake 54.2% 41.7% 37.2% 50.0% 5.8% 0.0% 37.6% 55.7% 17.1% 30.8% 27.8% 47.1% 28.6%
Positive Result 0 0 0 0 0 0 5 0 0 0 5 0 5
Test Positivity 0.0% 0.0% 0.0% 0.0% 0.0% – 2.0% 0.0% 0.0% 0.0% 0.7% 0.0% 0.7%
Population Prevalence Estimate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.5% 0.0% 0.0% 0.0% 0.1% 0.0% 0.1%

 


Table D.2.iii: Gonorrhea History, Testing and Outcome by
ORIGIN and REGION Web-IDSS† 2005 - 2006.
  Canadian Aboriginal Foreign-born Unknown Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
‡ -Numbers of new admissions / general population inmates in enhanced surveillance system

Number of New Admissions‡ 3,355 1,007 602 876 5,840
Previous Gonorrhea Test 514 293 122 150 1,020
Previous Test Uptake 15.3% 29.1% 5.5% 17.1% 17.5%
Previous Positive Gonorrhea 57 42 18 19 127
Previous Test Positivity 11.1% 14.3% 14.8% 12.7% 12.5%
Previous Gonorrhea Treated 45 30 17 17 101
Proportion Treated 78.9% 71.4% 94.4% 89.5% 79.5%
Gonorrhea Test on Admission 1,073 506 254 287 2,003
Testing Uptake 32.0% 50.2% 11.4% 32.8% 34.3%
Positive on Admission 6 2 0 3 11
Test Positivity 1.0% 0.6% 0.0% 1.6% 0.9%
LIFETIME PREVALENCE 1.9% 4.4% 0.8% 2.5% 2.4%
Number General Population 1,801 836 928 876 3,773
Gonorrhea Tests Among General Population 472 297 54 259 1,079
Gonorrhea Testing Uptake 26.2% 35.5% 5.8% 29.6% 28.6%
Positive Result 2 3 0 0 5
Test Positivity 0.2% 0.5% 0.0% 0.0% 0.2%
Population Prevalence Estimate 0.1% 0.4% 0.0% 0.0% 0.1%

 



Table D.3.i: Syphilis Case Reports among Inmates in Canadian Federal Penitentiaries by
GENDER and REGION, IDSS†, 2005 - 2006.


Syphilis
Atlantic Quebec Ontario Prairie Pacific Canada
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)

No. of Positive Test Reports 0 0 2 2 2 6 1 3 1 5 6 16
Male Cases 0 0 2 1 2 5 1 3 1 5 6 14
Male Prevalence Rate 0.00% 0.00% 0.07% 0.03% 0.06% 0.14% 0.04% 0.10% 0.06% 0.26% 0.05% 0.11%
Female Cases 0 0 0 1 0 1 0 0 0 0 0 2
Female Prevalence Rate 0.00% 0.00% 0.00% 1.22% 0.00% 0.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.45%
Overall Prevalence Rate 0.00% 0.00% 0.07% 0.06% 0.06% 0.17% 0.03% 0.10% 0.05% 0.25% 0.05% 0.12%

 


Table D.3.ii: Syphilis History, Testing and Outcome by GENDER and REGION Web-IDSS† 2005 - 2006.
  Atlantic Quebec Ontario Prairie Pacific CSC1a CSC1b
Males Females Males Females Males Females Males Females Males Females Males Females Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
‡ -Numbers of new admissions / general population inmates in the enhanced surveillance system
* - based on positive serology for VDRL
1a – For New Admissions: includes 41 Region unknown (38 males and 3 females); For General Population: includes 34 Region unknown (34 males and 0 females)
1b – For New Admissions: includes 16 gender unknown; For General Population: includes 7 gender unknown

Number of New Admissions‡ 410 51 948 45 2,229 1 1,474 174 417 34 5,516 308 5,840
Previous syphilis Test 47 15 285 21 375 0 341 74 67 8 1,127 120 1,248
Previous Test Uptake 11.5% 29.4% 30.1% 46.7% 16.8% 0.0% 23.1% 42.5% 16.1% 23.5% 20.4% 39.0% 21.4%
Previous Positive syphilis 1 0 2 1 10 0 9 4 6 0 29 6 36
Previous Test Positivity 2.1% 0.0% 0.7% 4.8% 2.7% – 2.6% 5.4% 9.0% 0.0% 2.6% 5.0% 2.9%
Previous syphilis Treated 1 0 0 1 4 0 5 2 3 0 14 3 17
Proportion Treated 100.0% – 0.0% 100.0% 40.0% – 55.6% 50.0% 50.0% – 48.3% 50.0% 47.2%
Syphilis Test on Admission 135 39 829 41 1,283 1 923 146 140 12 3,331 241 3,580
Syphilis Testing Uptake 32.9% 76.5% 87.4% 91.1% 57.6% 100.0% 62.6% 83.9% 33.6% 35.3% 60.4% 78.2% 61.3%
Positive Result* 0 0 0 0 3 0 0 1 1 0 4 1 5
Test Positivity 0.0% 0.0% 0.0% 0.0% 0.6% – 0.0% 1.1% 1.1% 0.0% 0.2% 0.6% 0.2%
Lifetime Prevalence 0.2% 0.0% 0.2% 2.2% 0.6% 0.0% 0.6% 2.9% 1.7% 0.0% 0.6% 2.3% 0.7%
Number General Population‡ 389 24 646 12 928 2 997 97 598 39 3,592 174 3,773
Syphilis Tests Among General Population 230 13 331 11 423 1 556 77 221 17 1,784 119 1,906
Syphilis Testing Uptake 59.1% 54.2% 51.2% 91.7% 45.6% 50. 0% 55.8% 79.4% 37.0% 43.6% 49.7% 68.4% 50.5%
Positive Result* 2 0 1 1 0 0 1 0 1 0 5 1 6
Test Positivity 1.1% 0.0% 0.4% 10.0% 0.0% 0.0% 0.2% 0.0% 0.7% 0.0% 0.4% 1.1% 0.4%
Population Prevalence Estimate 0.5% 0.0% 0.2% 8.3% 0.0% 0.0% 0.1% 0.0% 0.2% 0.0% 0.1% 0.6% 0.2%

 


Table D.3.iii: Syphilis History, Testing and Outcome by ORIGIN Web-IDSS† 2005 - 2006.

  Canadian Aboriginal Foreign-born Unknown Total

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
‡ - Numbers of new admissions / general population inmates in enhanced surveillance system
* - based on positive serology for VDRL

Number of New Admissions‡ 3,355 1,007 602 876 5,840
Previous syphilis Test 677 296 87 188 1,248
Previous Test Uptake 20.2% 29.4% 14.5% 21.5% 21.4%
Previous Positive syphilis 12 13 3 8 36
Previous Test Positivity 1.8% 4.4% 3.4% 4.3% 2.9%
Previous syphilis Treated 5 7 2 3 17
Proportion Treated 41.7% 53.8% 66.7% 37.5% 47.2%
Syphilis Test on Admission 2,033 686 344 517 3,580
Testing Uptake 60.6% 68.1% 57.1% 59.0% 61.3%
Positive Result* 1 2 2 0 5
Test Positivity 0.1% 0.4% 1.2% 0.0% 0.2%
Lifetime Prevalence 0.4% 1.5% 0.8% 0.9% 0.7%
Number General Population 1,801 836 260 876 3,773
Syphilis Tests Among General Population 917 451 130 408 1,906
Syphilis Testing Uptake 50.9% 53.9% 50.0% 46.6% 50.5%
Positive Result* 3 1 0 2 6
Test Positivity 0.4% 0.3% 0.0% 0.7% 0.4%
Population Prevalence Estimate 0.2% 0.1% 0.0% 0.2% 0.2%

 

Appendix E:
Tuberculosis Screening - Inmates


Table E.1: Reported TST Results on Initial Assessment by REGION – Inmates, Web-IDSS† 2005 - 2006

Freq (%)
TST Result
Atlantic Quebec Ontario Prairie Pacific Canada4
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Medically contraindicated (i.e., tuberculin allergy, etc)
2 - An invalid first TST includes a 'No show' for the read portion of the test or a negative read after 72 hours.
3 - An invalid second TST includes a 'No show' for the read portion of the test, a negative read after 72 hours, a second test not done, or a test administered outside of the 7 to 365 days of the first tuberculin administration.
4 - Total assessments for CSC overall (Canada) include 'Unknown' region (data not shown)for 2005 (N=56) and 2006 (N=181)

Tested Positive 25
(6.3%)
18
(4.5%)
184
(23.5%)
184
(27.3%)
67
(6.4%)
103
(12.0%)
96
(12.5%)
100
(10.7%)
20
(5.0%)
28
(8.0%)
401
(11.6%)
446
(13.3%)
Tested Negative 375
(93.8%)
386
(95.5%)
600
(76.5%)
491
(72.7%)
981
(93.6%)
752
(88.0%)
674
(87.5%)
836
(89.3%)
382
(95.0%)
321
(92.0%)
3,047
(88.4%)
2,914
(86.7%)
Previous Positive 6 10 11 11 4 7 34 18 6 4 61 52
Contraindicated1 2 2 13 11 10 10 7 13 4 0 36 37
Invalid 65
(12.9%)
67
(13.0%)
57
(5.6%)
118
(12.4%)
58
(4.5%)
137
(12.2%)
157
(14.8%)
217
(17.3%)
35
(7.3%)
36
(8.7%)
379
(8.6%)
605
(13.6%)
Invalid TST-12 21 27 13 35 18 27 48 70 10 12 111 178
Invalid TST-23 44 40 44 83 40 110 109 147 25 24 268 427
Refused TST 11
(2.2%)
10
(1.9%)
83
(8.1%)
88
(9.2%)
8
(0.6%)
5
(0.4%)
30
(2.8%)
17
(1.4%)
8
(1.7%)
1
(0.2%)
141
(3.2%)
121
(2.7%)
Blank / Unknown 20 21 73 50 147 107 60 55 23 22 327 262
TOTAL (%) 504
(11.5%)
514
(11.6%)
1,021
(23.2%)
953
(21.5%)
1,275
(29.0%)
1,121
(25.3%)
1,058
(24.1%)
1,256
(28.3%)
478
(10.9%)
412
(9.3%)
4,392 4,437

 


Table E.2: BCG Vaccination Status1 by ORIGIN and REGION – Inmates, Web-IDSS† 2005 - 2006


Freq (%)
Origin
Atlantic Quebec Ontario Prairie Pacific Canada
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 – Percentage who report a history of BCG vaccination on Initial Assessment (as part of the
TB medical history).

Canadian Born 1.0% 1.0% 32.1% 27.5% 1.2% 2.6% 7.0% 6.5% 10.1% 2.5% 11.6% 9.6%
Aboriginal 5.9% 3.4% 23.2% 18.2% 1.5% 4.0% 11.8% 10.2% 17.5% 0.0% 11.1% 8.0%
Foreign Born 4.4% 7.7% 17.6% 20.5% 15.8% 13.3% 17.9% 25.6% 10.3% 6.5% 15.0% 16.2%
Unknown 0.0% 0.0% 20.0% 16.7% 2.4% 5.2% 4.8% 12.9% 4.4% 4.6% 8.3% 9.6%
Total (%) 1.4% 4.3% 29.0% 24.9% 4.2% 5.0% 9.2% 10.0% 10.7% 2.7% 11.6% 9.9%

 


Table E.3: Reported TST Results on Ongoing Negative Assessment by REGION – Inmates, Web-IDSS† 2005 - 2006

Freq (%)
TST Result
Atlantic Quebec Ontario Prairie Pacific Canada3
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Medically contraindicated (i.e., tuberculin allergy, etc)
2 - An invalid first TST includes a 'No show' for the read portion of the test or a negative read after 72 hours.
3 - Totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=116) and 2006 (N=244)

Tested Positive 7
(1.0%)
5
(0.7%)
9
(0.8%)
17
(1.3%)
13
(0.9%)
13
(0.7%)
48
(2.5%)
45
(2.4%)
14
(1.8%)
19
(2.2%)
93
(1.5%)
103
(1.5%)
Tested Negative 678
(99.0%)
683
(99.3%)
1,143
(99.2%)
1,280
(98.7%)
1,498
(99.1%)
1,935
(99.3%)
1,853
(97.5%)
1,804
(97.6%)
748
(98.2%)
845
(97.8%)
6,007
(98.5%)
6,753
(98.5%)
Contraindicated1 3 5 5 20 55 23 12 14 5 6 80 68
Invalid TST-12 23
(2.9%)
22
(2.8%)
63
(3.8%)
32
(1.8%)
58
(2.5%)
45
(1.6%)
62
(2.8%)
85
(3.6%)
84
(7.7%)
94
(8.7%)
297
(3.6%)
287
(3.2%)
Refused TST 48
(6.1%)
38
(4.8%)
275
(16.8%)
286
(16.0%)
73
(3.1%)
78
(2.8%)
104
(4.7%)
126
(5.3%)
86
(7.9%)
58
(5.4%)
591
(7.2%)
599
(6.6%)
Blank / Unknown 34 39 146 150 631 654 136 298 149 54 1,111 1,207
TOTAL (%) 793
(9.7%)
792
(8.8%)
1,641
(20.1%)
1,758
(19.8%)
2,328
(28.5%)
2,748
(30.5%)
2,215
(27.1%)
2,372
(26.3%)
1,086
(13.3%)
1,076
(11.9%)
8,179 9,017

 


Table E.4: LTBI1 by AGE GROUP and REGION – Inmates, Web-IDSS† 2005 - 2006

Freq (%)2
Age Group
Atlantic Quebec Ontario Prairie Pacific Canada3
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Includes all inmates with positive TST result, either newly diagnosed on Initial and Ongoing Negative Assessments, Previous positive on Initial Assessment, and Ongoing Positive Assessments.
2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per age group and region.
3 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=191) and 2006 (N=443).

Missing 3
(25.0%)
0
(0.0%)
1
(50.0%)
1
(14.3%)
1
(9.1%)
1
(9.1%)
0
(0.0%)
2
(7.1%)
2
(18.2%)
1
(8.3%)
8
(11.9%)
5
(6.3%)
17-19 1
(2.6 %)
1
(2.6%)
6
(17.1%)
8
(30.8%)
4
(10.0%)
6
(17.6%)
9
(10.2%)
3
(4.2%)
2
(15.4%)
1
(7.1%)
22
(10.2%)
20
(10.5%)
20-29 11
(2.3%)
12
(2.6%)
71
(10.3%)
81
(11.6%)
81
(7.0%)
132
(11.1%)
180
(12.0%)
175
(10.6%)
26
(5.8%)
28
(7.3%)
379
(8.7%)
435
(9.7%)
30-39 25
(6.5%)
21
(5.4%)
154
(14.7%)
182
(17.4%)
159
(12.6%)
178
(14.6%)
197
(18.0%)
216
(18.5%)
41
(8.2%)
44
(9.3%)
583
(13.4%)
655
(14.8%)
40-49 39
(14.4%)
31
(11.0%)
252
(28.3%)
287
(29.8%)
162
(16.5%)
172
(17.2%)
206
(29.4%)
182
(23.7%)
59
(15.4%)
54
(14.5%)
734
(22.3%)
739
(21.2%)
50-59 24
(20.5%)
30
(23.3%)
134
(38.7%)
164
(41.2%)
64
(17.7%)
99
(24.9%)
74
(36.3%)
71
(29.7%)
29
(16.5%)
39
(23.1%)
331
(27.1%)
418
(30.0%)
60 + 9
(18.8%)
4
(10.0%)
44
(40.0%)
65
(42.8%)
43
(25.3%)
42
(26.4%)
25
(36.8%)
20
(29.4%)
19
(27.9%)
15
(21.7%)
141
(29.9%)
149
(29.6%)
TOTAL (%) 112
(8.3%)
99
(7.3%)
662
(21.2%)
788
(23.9%)
514
(12.9%)
630
(15.7%)
691
(18.7%)
669
(16.8%)
178
(11.1%)
182
(12.2%)
2,198
(15.8%)
2,421
(16.6%)

 


Table E.5: LTBI1 by ORIGIN and REGION – Inmates, Web-IDSS† 2005 - 2006

Freq (%)2
Origin
Atlantic Quebec Ontario Prairie Pacific Canada3
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Includes all inmates with a positive TST result, either newly diagnosed on Initial or Ongoing Negative Assessments, Previous positive on Initial Assessment, or Ongoing Positive Assessments.
2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per origin group and region.
3 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=191) and 2006 (N=443).

Canadian Born 50
(6.2%)
32
(3.8%)
288
(16.6%)
357
(19.3%)
130
(6.6%)
195
(9.4%)
106
(9.2%)
97
(7.4%)
27
(4.4%)
34
(5.8%)
612
(9.6%)
735
(10.7%)
Aboriginal 13
(12.6%)
17
(14.3%)
48
(23.4%)
47
(23.0%)
74
(16.0%)
51
(13.7%)
388
(24.1%)
371
(23.2%)
50
(14.3%)
48
(14.9%)
588
(21.2%)
542
(20.0%)
Foreign Born 12
(37.5%)
7
(30.4%)
80
(43.0%)
104
(49.5%)
156
(29.5%)
213
(41.4%)
59
(45.4%)
62
(38.5%)
39
(36.1%)
35
(42.7%)
355
(35.6%)
433
(42.5%)
Unknown 37
(8.8%)
43
(11.2%)
246
(24.8%)
280
(27.2%)
154
(15.1%)
171
(16.2%)
138
(17.3%)
139
(15.2%)
62
(11.8%)
65
(12.9%)
643
(16.9%)
711
(17.8%)
Total (%) 112
(8.3%)
99
(7.3%)
662
(21.2%)
788
(23.9%)
514
(12.9%)
630
(15.7%)
691
(18.7%)
669
(16.8%)
178
(11.1%)
182
(12.2%)
2,198
(15.8%)
2,421
(16.6%)

 



Table E.6: LTBI1 by GENDER and REGION – Inmates, Web-IDSS† 2005 - 2006

 Freq (%)2
Gender
Atlantic Quebec Ontario Prairie Pacific3 Canada4
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Includes all inmates with a positive TST result, either newly diagnosed on Initial or Ongoing Negative Assessments, Previous positive on Initial Assessment, or Ongoing Positive Assessments.
2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per gender and region.
3 – Prior to April 1st 2004, federally sentenced women in Pacific region were generally kept in a provincial institution.
4 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=191) and 2006 (N=443).

Male 108
(8.4%)
89
(7.0%)
647
(21.6%)
782
(24.4%)
506
(13.2%)
618
(16.0%)
668
(19.1%)
642
(17.0%)
177
(11.2%)
182
(12.2%)
2,150
(16.1%)
2,349
(16.8%)
Female 4
(6.0%)
10
(10.9%)
6
(7.0%)
5
(6.3%)
8
(5.3%)
10
(7.0%)
23
(11.7%)
26
(12.7%)
1
(7.1%)
0
(0.0%)
47
(8.4%)
68
(11.3%)
Unknown 0
(0.0%)
0
(0.0%)
1
(33.3%)
1
(33.3%)
0
(0.0%)
2
(20.0%)
0
(0.0%)
1
(9.1%)
0
(0.0%)
0
(0.0%)
1
(5.6%)
4
(12.5%)
Total (%) 112
(8.3%)
99
(7.3%)
662
(21.2%)
788
(23.9%)
514
(12.9%)
630
(15.7%)
691
(18.7%)
669
(16.8%)
178
(11.1%)
182
(12.2%)
2,198
(15.8%)
2,421
(16.6%)

 


Table E.7.i: Reported Comorbidity / Risk Factors1 and Symptoms1 by TST Result –
Inmates, Web-IDSS† 2005


Test Type
Positive2 Previous
Positive3
Ongoing
Positive
Sub-Total Negative Other4 Sub-total TOTAL
  N= 494 N= 61 N= 1,643 N= 2,198 N= 9,054 N= 2,962 N= 12,016 N= 14,214

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Numbers in the table reflect those answering 'Yes' to the risk factor / symptom
(individuals may report multiple risk factors / symptoms).

2 - Includes newly positive TST results from Initial and Ongoing Negative assessments.
3 – Previously positive TST accepted on Initial Assessment – see Table E.1.
4 - 'Other' result includes medically contraindicated, invalid TST-1, invalid TST-2
(second of two-step TST), refused, and blank/unknown.

Risks
Diabetes 14 2 63 79 193 47 240 319
  (2.83%) (3.28%) (3.83%) (3.59%) (2.13%) (1.59%) (2.00%) (2.24%)
Hemodialysis 0 0 2 2 12 2 14 16
  (0.0%) (0.0%) (0.12%) (0.09%) (0.13%) (0.07%) (0.12%) (0.11%)
Silicosis 1 0 3 4 4 1 5 9
  (0.2%) (0.0%) (0.18%) (0.18%) (0.04%) (0.03%) (0.04%) (0.06%)
Transplant 1 0 5 6 15 3 18 24
  (0.2%) (0.0%) (0.30%) (0.27%) (0.17%) (0.1%) (0.15%) (0.17%)
Injection Drug User 58 8 138 204 1121 335 1,456 1,660
  (11.74%) (13.11%) (8.4%) (9.28%) (12.38%) (11.31%) (12.12%) (11.68%)
Lymphoma 3 0 4 7 14 6 20 27
  (0.61%) (0.0%) (0.24%) (0.32%) (0.15%) (0.2%) (0.17%) (0.19%)
HIV/AIDS 1 1 17 19 147 40 187 206
  (0.2%) (1.64%) (1.03%) (0.86%) (1.62%) (1.35%) (1.56%) (1.45%)
Chemotherapy 2 1 5 8 60 13 73 81
  (0.4%) (1.64%) (0.3%) (0.36%) (0.66%) (0.44%) (0.61%) (0.57%)
Steroids 7 1 13 21 166 50 26 237
  (1.42%) (1.64%) (0.79%) (0.96%) (1.83%) (1.69%) (1.80%) (1.67%)
TB Case Contact 11 2 45 58 118 49 167 225
  (2.23%) (3.28%) (2.74%) (2.64%) (1.30%) (1.65%) (1.39%) (1.58%)
TOTAL 98 15 295 408 1,850 546 2,396 2,804
Symptoms
Fatigue 33 6 143 182 493 211 704 886
  (6.68%) (9.84%) (8.70%) (8.28%) (5.45%) (7.12%) (5.86%) (6.23%)
Fever 6 0 17 23 59 22 81 104
  (1.21%) (0.0%) (1.03%) (1.05%) (0.65%) (0.74%) (0.67%) (0.73%)
Weight Loss 14 1 67 82 259 83 342 424
  (2.83%) (1.64%) (4.08%) (3.73%) (2.86%) (2.8%) (2.85%) (2.98%)
Loss of Appetite 20 0 82 102 286 73 359 461
  (4.05%) (0.0%) (4.99%) (4.64%) (3.16%) (2.46%) (2.99%) (3.24%)
Night Sweats 32 1 76 109 334 72 406 515
  (6.478%) (1.64%) (4.63%) (4.96%) (3.69%) (2.43%) (3.38%) (3.62%)
Hoarseness 20 1 61 82 183 41 224 306
  (4.05%) (1.64%) (3.71%) (3.73%) (2.02%) (1.38%) (1.86%) (2.15%)
Productive Cough 21 2 115 138 312 79 391 529
  (4.25%) (3.28%) (7.00%) (6.28%) (3.45%) (2.67%) (3.25%) (3.72%)
Coughing Blood 4 0 20 24 52 14 66 90
  (0.81%) (0.0%) (1.22%) (1.09%) (0.57%) (0.47%) (0.55%) (0.63%)
Chest Pains 20 4 122 146 409 118 527 673
  (4.05%) (6.56%) (7.43%) (6.64%) (4.52%) (3.98%) (4.39%) (4.73%)
Total 170 15 703 888 2,387 713 3,100 3,988

 


Table E.7.ii: Reported Comorbidity / Risk Factors1 and Symptoms1 by TST Result –
Inmates, Web-IDSS† 2006


Test Type
Positive2 Previous
Positive3
Ongoing
Positive
Sub-Total Negative Other4 Sub-total TOTAL
  N= 549 N= 52 N= 1,820 N= 2,421 N= 9,667 N= 3,186 N= 12,853 N= 15,274

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Numbers in the table reflect those answering 'Yes' to the risk factor / symptom
(individuals may report multiple risk factors / symptoms).

2 - Includes newly positive TST results from Initial and Ongoing Negative assessments.
3 – Previously positive TST accepted on Initial Assessment – see Table E.1.
4 - 'Other' result includes medically contraindicated, invalid TST-1, invalid TST-2 (second of two-step TST), refused, and blank/unknown.

Risks
Diabetes 23 2 97 122 291 89 380 502
  (4.19%) (3.85%) (5.33%) (5.04%) (3.01%) (2.79%) (2.96%) (3.29%)
Hemodialysis 1 0 2 3 14 6 20 23
  (0.18%) (0.0%) (0.11%) (0.12%) (0.14%) (0.19%) (0.16%) (0.15%)
Silicosis 0 0 1 1 3 3 6 7
  (0.0%) (0.0%) (0.05%) (0.04%) (0.03%) (0.09%) (0.05%) (0.05%)
Transplant 3 0 4 7 16 6 22 29
  (0.55%) (0.0%) (0.22%) (0.29%) (0.17%) (0.19%) (0.17%) (0.19%)
Injection Drug User 75 6 186 267 1,335 391 1,726 1,993
  (13.68%) (11.54%) (10.22%) (11.03%) (13.81%) (12.27%) (13.43%) (13.05%)
Lymphoma 1 0 4 5 15 4 19 24
  (0.18%) (0.0%) (0.22%) (0.21%) (0.16%) (0.13%) (0.15%) (0.16%)
HIV/AIDS 3 1 20 24 153 45 198 222
  (0.55%) (1.92%) (1.10%) (0.99%) (1.58%) (1.41%) (1.54%) (1.45%)
Chemotherapy 4 0 9 13 59 15 74 87
  (0.73%) (0.0%) (0.49%) (0.54%) (0.61%) (0.47%) (0.58%) (0.57%)
Steroids 4 1 21 26 221 52 273 299
  (0.73%) (1.92%) (1.15%) (1.07%) (2.29%) (1.63%) (2.12%) (1.96%)
TB Case Contact 10 2 85 97 319 60 379 476
  (1.82%) (3.85%) (4.67%) (4.01%) (3.30%) (1.88%) (2.95%) (3.12%)
Total 124 12 429 565 2,426 671 3,097 3,662
Symptoms
Fatigue 25 4 116 145 484 199 603 748
  (4.55%) (7.69%) (6.37%) (5.99%) (5.01%) (3.74%) (4.69%) (4.90%)
Fever 6 0 20 26 62 21 83 109
  (1.09%) (0.0%) (1.10%) (1.07%) (0.64%) (0.66%) (0.65%) (0.71%)
Weight Loss 11 2 76 89 299 93 392 481
  (2.00%) (3.85%) (4.18%) (3.68%) (3.09%) (2.92%) (3.05%) (3.15%)
Loss of Appetite 20 2 87 109 300 87 387 496
  (3.64%) (3.85%) (4.78%) (4.50%) (3.10%) (2.73%) (3.01%) (3.25%)
Night Sweats 17 1 78 96 331 80 411 507
  (3.10%) (1.92%) (4.29%) (3.97%) (3.42%) (2.51%) (3.20%) (3.32%)
Hoarseness 12 0 57 69 147 41 188 257
  (2.19%) (0.0%) (3.13%) (2.85%) (1.52%) (1.29%) (1.46%) (1.68%)
Productive Cough 13 3 103 119 322 74 396 515
  (2.37%) (5.77%) (5.66%) (4.92%) (3.33%) (2.32%) (3.08%) (3.37%)
Coughing Blood 3 0 11 14 62 24 86 100
  (0.55%) (0.0%) (0.60%) (0.58%) (0.64%) (0.75%) (0.67%) (0.65%)
Chest Pains 28 3 95 126 389 108 497 623
  (5.10%) (5.77%) (5.22%) (5.20%) (4.02%) (3.39%) (3.87%) (4.08%)
Total 135 15 643 793 2,396 647 3,043 3,836

 


Table E.8: Treatment Uptake for Latent Tuberculosis Infection – Inmates, IDSS† 2005 - 2006

 Freq (%)
Gender
Atlantic Quebec Ontario Prairie Pacific Canada
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Aggregate Infectious Disease Surveillance System (IDSS)

Number of Inmates with LTBI 109 99 654 777 507 627 683 653 171 181 2,165 2,389
Average Number on LTBI Therapy per Month 4 3 8 5 53 50 21 32 13 15 99 103

 

Appendix F:
Tuberculosis Screening - Staff


Table F.1: Reported TST Results on Initial Assessment by REGION – Staff, Web-IDSS† 2005 - 2006

Freq (%)
TST Result
Atlantic Quebec Ontario Prairie Pacific Canada4
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Medically contraindicated (i.e., tuberculin allergy etc)
2 - An invalid first TST includes a 'No show' for the read portion of the test or a negative read after 72 hours.
3 - An invalid second TST includes a 'No show' for the read portion of the test, a negative read after 72 hours, a second test not done, or a test administered outside of the 7 to 365 days of the first tuberculin administration.
4 – Total assessments for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=155) and 2006 (N=86)

Tested Positive 2
(11.8%)
4
(6.9%)
9
(22.5%)
10
(19.2%)
3
(5.1%)
4
(3.0%)
5
(13.2%)
6
(3.9%)
0
(0.0%)
1
(2.9%)
23
(8.2%)
28
(5.7%)
Tested Negative 15
(88.2%)
54
(93.1%)
31
(77.5%)
42
(80.8%)
56
(94.9%)
131
(97.0%)
32
(86.5%)
147
(96.1%)
1
(100%)
34
(97.1%)
258
(91.8%)
463
(94.3%)
Previous Positive 1 4 1 2 2 5 1 12 2 3 10 21
Contraindicated1 0 0 0 0 0 0 0 1 0 0 0 2
Invalid 11
(37.9%)
6
(8.8%)
15
(25.4%)
4
(6.9%)
22
(26.2%)
14
(8.8%)
21
(34.4%)
51
(22.5%)
13
(72.2%)
24
(37.5%)
105
(25.9%)
118
(17.8%)
Invalid TST-12 0 2 3 0 4 2 2 8 6 7 22 23
Invalid TST-23 11 4 12 4 18 12 19 43 7 17 83 95
Refused TST 0
(0.0%)
0
(0.0%)
1
(1.7%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
1
(0.2%)
2
(0.3%)
Blank / Unknown 0 0 2 0 1 6 2 10 2 2 9 23
TOTAL (%) 29
(7.1%)
68
(10.3%)
59
(14.5%)
58
(8.7%)
84
(20.7%)
160
(24.1%)
61
(15.0%)
227
(34.2%)
18
(4.4%)
64
(9.7%)
406 663

 


Table F.2: BCG Vaccination Status1 by ORIGIN and REGION – Inmates Staff, Web-IDSS† 2005 - 2006

Freq (%)
Origin
Atlantic Quebec Ontario Prairie Pacific Canada
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 – Percentage who report a history of BCG vaccination on Initial Assessment
(as part of the TB medical history).

Canadian Born 0.0% 3.5% 28.9% 24.0% 0.0% 8.7% 0.0% 1.8% 8.3% 3.9% 6.4% 6.9%
Aboriginal 0.0% 0.0% 0.0% 100% 0.0% 22.2% 7.7% 0.0% 0.0% 0.0% 6.7% 8.3%
Foreign Born 100% 0.0% 50.0% 0.0% 0.0% 0.0% 0.0% 27.3% 0.0% 28.6% 11.1% 22.2%
Unknown 0.0% 12.5% 50.0% 25.0% 25.0% 9.1% 0.0% 9.1% 33.3% 0.0% 25.0% 12.2%
Total (%) 3.5% 4.4% 33.9% 24.1% 2.4% 9.4% 1.6% 3.1% 11.1% 6.3% 8.4% 8.0%

 


Table F.3: Reported TST Results on Ongoing Negative Assessment by REGION – Staff, Web-IDSS† 2005 - 2006

Freq (%)
TST Result
Atlantic Quebec Ontario Prairie Pacific Canada3
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Medically contraindicated (i.e., tuberculin allergy etc)
2 - An invalid first TST includes a 'No show' for the read portion of the test or a negative read after 72 hours.
3 - Totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=164) and 2006 (N=182)

Tested Positive 6
(1.5%)
2
(0.4%)
5
 (8.2%)
12
(7.7%)
3
(0.9%)
1
(0.3%)
1
(0.8%)
8
(1.2%)
2
(1.4%)
3
(3.1%)
19
(1.6%)
31
(1.7%)
Tested Negative 385
(98.5%)
494
(99.6%)
56
(91.8%)
144
(92.3%)
341
(99.1%)
320
(99.7%)
124
(99.2%)
643
(98.8%)
137
(98.6%)
93
(96.9%)
1,164
(98.4%)
1,844
(98.3%)
Contraindicated1 0 0 0 0 0 1 1 6 0 1 1 8
Invalid TST-12 22
(5.2%)
13
(2.5%)
3
(4.6%)
2
(1.3%)
44
(11.1%)
34
(9.3%)
19
(12.5%)
43
(5.9%)
166
(53.0%)
126
(56.3%)
290
(19.2%)
242
(11.1%)
Refused TST 4
(0.9%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
1
(0.7%)
1
(0.1%)
1
(0.3%)
0
(0.0%)
6
(0.4%)
2
(0.1%)
Blank / Unknown 7 5 1 1 8 11 6 34 7 1 34 54
TOTAL (%) 424
(28.0%)
514
(23.6%)
65
(4.3%)
159
(7.3%)
396
(26.2%)
367
(16.8%)
152
(10.0%)
735
(33.7%)
313
(20.7%)
224
(10.3 %)
1,514 2,181

 


Table F.4: LTBI1 by AGE GROUP and REGION – Staff, Web-IDSS† 2005 - 2006

Freq (%)2
Age Group
Atlantic Quebec Ontario Prairie Pacific Canada3
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Includes all inmates with a positive TST result, either newly diagnosed on Initial and Ongoing Negative Assessments, Previous positive on Initial Assessment, and Ongoing Positive Assessments.
2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per age group and region.
3 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=325) and 2006 (N=278)

Missing 0
(0.0%)
0
(0.0%)
0
 (0.0%)
0
(0.0%)
1
 (25.0%)
1
(10.0%)
1
(33.3%)
3
(15.0%)
0
(0.0%)
0
(0.0%)
3
(15%)
4
(9.1%)
17-19 0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
20-29 0
(0.0%)
1
(1.7%)
1
(5.9%)
2
(10.5%)
3
(4.4%)
2
(1.6%)
2
(5.9%)
7
(5.0%)
0
(0.0%)
2
(.4%)
10
(3.3%)
16
(3.6%)
30-39 7
(5.3%)
4
(2.4%)
4
(8.3%)
5
(7.9%)
4
 (2.5%)
5
(3.0%)
11
(12.1%)
18
(5.8%)
3
(3.3%)
2
(2.1%)
31
(5.1%)
38
(4.3%)
40-49 10
(6.3%)
14
(6.3%)
9
(20.5%)
10
(11.6%)
2
(1.3%)
7
(5.2%)
11
(16.7%)
30
(9.4%)
4
(4.7%)
5
(8.2%)
41
(7.1%)
74
(8.2%)
50-59 3
(2.6%)
5
(3.7%)
3
(18.8%)
6
(13.6%)
6
(6.1%)
4
(5.0%)
13
(28.9%)
29
(14.1%)
9
(8.7%)
3
(4.8%)
36
(8.5%)
53
(9.0%)
60 + 4
(28.6%)
5
(27.8%)
0
(0.0%)
1
(25.0%)
2
(20.0%)
0
(0.0%)
1
(16.7%)
3
(10.0%)
1
(6.7%)
0
(0.0%)
10
(20.0%)
10
(12.8%)
TOTAL (%) 24
(5.1%)
29
(4.8%)
17
(13.5%)
24
(11.1%)
18
(3.7%)
19
(3.6%)
39
(15.9%)
90
(8.8%)
17
(5.0%)
21
(4.1%)
131
(6.6%)
195
(6.6%)

 


Table F.5: LTBI1 by ORIGIN and REGION – Staff, Web-IDSS† 2005 - 2006

Freq (%)2
Origin
Atlantic Quebec Ontario Prairie Pacific Canada3
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Includes all inmates with a positive TST result, either newly diagnosed on Initial or Ongoing Negative Assessments, Previous positive on Initial Assessment, or Ongoing Positive Assessments.
2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per origin group and region.
3 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=325) and 2006 (N=278)

Canadian Born 3
(2.6%)
8
(4.2%)
10
(11.1%)
19
(13.4%)
4
(3.3%)
5
(2.4%)
6
(8.3%)
19
(6.0%)
1
(1.1%)
4
(3.2%)
32
(4.9%)
61
(5.6%)
Aboriginal 0
(0.0%)
1
(16.7%)
0
(0.0%)
0
(0.0%)
0
(0.0%)
1
(7.7%)
4
(18.2%)
7
(9.9%)
1
(6.7%)
0
(0.0%)
5
(7.7%)
10
(9.2%)
Foreign Born 1
(100.0%)
0
(0.0%)
0
(0.0%)
1
(20.0%)
1
(14.3%)
0
(0.0%)
5
(55.6%)
5
(26.3%)
1
(10.0%)
1
(6.7%)
12
(22.2%)
10
(16.1%)
Unknown 20
(5.8%)
20
(5.0%)
7
(23.3%)
4
(6.2%)
13
(3.7%)
13
(4.4%)
24
(16.9%)
59
(9.6%)
14
(6.1%)
7
(4.8%)
82
(6.7%)
114
(6.8%)
Total (%) 24
(5.1%)
29
(4.8%)
17
(13.5%)
24
(11.1%)
18
(3.7%)
19
(3.6%)
39
(15.9%)
90
(8.8%)
17
(5.0%)
12
(4.1%)
131
(6.6%)
195
(6.6%)

 

Table F.6: LTBI1 by GENDER and REGION – Staff, Web-IDSS† 2005 - 2006

 Freq (%)2
Gender
Atlantic Quebec Ontario Prairie Pacific3 Canada4
2005 2006 2005 2006 2005 2006 2005 2006 2005 2006 2005 2006

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Includes all inmates with a positive TST result, either newly diagnosed on Initial or Ongoing Negative Assessments, Previous positive on Initial Assessment, or Ongoing Positive Assessments.
2 – Frequency calculated by dividing the number positive by the number of inmates participating in TB screening per gender and region.
3 – Prior to April 1st 2004, federally sentenced women in Pacific region were generally kept in a provincial institution.
4 – LTBI totals for CSC overall (Canada) include 'Unknown' region (data not shown) for 2005 (N=325) and 2006 (N=278)

Male 11
(5.6%)
12
(4.4%)
5
(11.1%)
15
(14.3%)
13
(5.3%)
9
(3.1%)
20
(16.3%)
44
(8.4%)
11
(5.7%)
3
(2.0%)
67
(6.9%)
93
(6.4%)
Female 12
(4.6%)
16
(5.1%)
12
(15.0%)
9
(8.4%)
4
(1.9%)
6
(3.2%)
19
(15.8%)
30
(8.5%)
6
(4.3%)
8
(6.7%)
61
(6.3%)
79
(6.5%)
Unknown 1
(14.3%)
1
(5.9%)
0
(0.0%)
0
(0.0%)
1
(3.2%)
4
(7.5%)
0
(0.0%)
16
(10.7%)
0
(0.0%)
1
(4.0%)
3
(5.0%)
23
(8.6%)
Total (%) 24
(5.1%)
29
(4.8%)
17
(13.5%)
24
(11.1%)
18
(3.7%)
19
(3.6%)
39
(15.9%)
90
(8.8%)
17
(5.0%)
12
(4.1%)
131
(6.6%)
195
(6.6%)

 

Table F.7.i: Reported Comorbidity / Risk Factors1 and Symptoms1
by TST Result – Staff, Web-IDSS† 2005


Test Type
Positive2 Previous
Positive3
Ongoing
Positive
Sub-Total Negative Other4 Sub-total TOTAL
N= 42 N= 10 N= 79 N= 131 N= 1,422 N= 446 N= 1,868 N= 1,999

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Numbers in the table reflect those answering 'Yes' to the risk factor / symptom
(individuals may report multiple risk factors / symptoms).

2 - Includes newly positive TST results from Initial and Ongoing Negative assessments.
3 – Previously positive TST accepted on Initial Assessment – see Table F.1.
4 - 'Other' result includes medically contraindicated, invalid TST-1, invalid TST-2
(second of two-step TST), refused, and blank/unknown.

Risks
Diabetes 0 1 3 4 31 21 52 56
  (0.00%) (10.00%) (3.80%) (3.05%) (2.18%) (4.71%) (2.78%) (2.80%)
Hemodialysis 0 0 1 1 0 0 0 1
  (0.00%) (0.00%) (1.27%) (0.76%) (0.00%) (0.00%) (0.00%) (0.05%)
Silicosis 0 0 0 0 0 0 0 0
  (0.00%) (0.00%) (0.00%) (0.00%) (0.00%) (0.00%) (0.00%) (0.00%)
Transplant 0 0 0 0 0 1 1 1
  (0.00%) (0.00%) (0.00%) (0.00%) (0.00%) (0.22%) (0.05%) (0.05%)
Injection Drug User 0 0 0 0 6 1 7 7
  (0.00%) (0.00%) (0.00%) (0.00%) (0.42%) (0.22%) (0.37%) (0.35%)
Lymphoma 1 0 0 1 0 0 0 1
  (2.38%) (0.00%) (0.00%) (0.76%) (0.00%) (0.00%) (0.00%) (0.05%)
HIV/AIDS 0 0 0 0 7 1 8 8
  (0.00%) (0.00%) (0.00%) (0.00%) (0.49%) (0.22%) (0.43%) (0.40%)
Chemotherapy 1 0 0 1 2 1 3 4
  (2.38%) (0.00%) (0.00%) (0.76%) (0.14%) (0.22%) (0.16%) (0.20%)
Oral Steroids 2 0 2 4 23 1 24 28
  (4.76%) (0.00%) (2.53%) (3.05%) (1.62%) (0.22%) (1.28%) (1.40%)
TB Case Contact 3 0 3 6 38 13 51 57
  (7.14%) (0.00%) (3.80%) (4.58%) (2.67%) (2.91%) (2.73%) (2.85%)
Total 7 1 9 17 107 39 146 163
Symptoms
Fatigue 1 0 5 6 18 4 22 28
  (2.38%) (0.00%) (6.33%) (4.58%) (1.27%) (0.90%) (1.18%) (1.40%)
Fever 0 0 1 0 3 1 4 4
  (0.00%) (0.00%) (1.27%) (0.00%) (0.21%) (0.22%) (0.21%) (0.20%)
Weight Loss 0 0 1 1 6 2 8 9
  (0.00%) (0.00%) (1.27%) (0.76%) (0.42%) (0.45%) (0.43%) (0.45%)
Loss of Appetite 0 0 0 0 6 2 8 8
  (0.00%) (0.00%) (0.00%) (0.00%) (0.42%) (0.45%) (0.43%) (0.40%)
Night Sweats 0 0 5 5 14 4 18 23
  (0.00%) (0.00%) (6.33%) (3.82%) (0.98%) (0.90%) (0.96%) (1.15%)
Hoarseness 2 0 2 4 20 3 23 27
  (4.76%) (0.00%) (2.53%) (3.05%) (1.41%) (0.67%) (1.23%) (1.35%)
Productive Cough 0 0 3 3 36 10 46 49
  (0.00%) (0.00%) (3.80%) (2.29%) (2.53%) (2.24%) (2.46%) (2.45%)
Coughing Blood 0 0 0 0 1 2 3 3
  (0.00%) (0.00%) (0.00%) (0.00%) (0.07%) (0.45%) (0.16%) (0.15%)
Chest pains 0 0 1 1 19 4 23 24
  (0.00%) (0.00%) (1.27%) (0.76%) (1.34%) (0.90%) (1.23%) (1.20%)
Total 3 0 18 20 123 32 155 176

 


Table F.7.ii: Reported Comorbidity / Risk Factors1 and Symptoms1
by TST Result – Staff, Web-IDSS† 2006


Test Type
Positive2 Previous
Positive3
Ongoing
Positive
Sub-Total Negative Other4 Sub-total TOTAL
N= 59 N= 27 N= 107 N= 193 N= 2,307 N= 451 N= 2,758 N= 2,951

† - Enhanced Surveillance line-listed Web-enabled Infectious Disease Surveillance System (Web-IDSS)
1 - Numbers in the table reflect those answering 'Yes' to the risk factor / symptom
(individuals may report multiple risk factors / symptoms).

2 - Includes newly positive TST results from Initial and Ongoing Negative assessments.
3 – Previously positive TST accepted on Initial Assessment – see Table F.1
4 - 'Other' result includes medically contraindicated, invalid TST-1, invalid TST-2
(second of two-step TST), refused, and blank/unknown.

Risks
Diabetes 1 0 2 3 71 10 81 84
  (1.69%) (0.00%) (1.87%) (1.55%) (3.08%) (2.22%) (2.94%) (2.85%)
Hemodialysis 0 1 2 3 1 0 1 4
  (0.00%) (3.70%) (1.87%) (1.55%) (0.04%) (0.00%) (0.04%) (0.14%)
Silicosis 0 0 0 0 0 0 0 0
  (0.00%) (0.00%) (0.00%) (0.00%) (0.00%) (0.00%) (0.00%) (0.00%)
Transplant 0 1 0 1 3 0 3 4
  (0.00%) (3.70%) (0.00%) (0.52%) (0.13%) (0.00%) (0.11%) (0.14%)
Injection Drug User 0 0 0 0 4 0 4 4
  (0.00%) (0.00%) (0.00%) (0.00%) (0.17%) (0.00%) (0.15%) (0.14%)
Lymphoma 0 0 0 0 6 1 7 7
  (0.00%) (0.00%) (0.00%) (0.00%) (0.26%) (0.22%) (0.25%) (0.24%)
HIV/AIDS 0 0 0 0 4 1 5 5
  (0.00%) (0.00%) (0.00%) (0.00%) (0.17%) (0.22%) (0.18%) (0.17%)
Chemotherapy 0 1 2 3 6 1 7 10
  (0.00%) (3.70%) (1.87%) (1.55%) (0.26%) (0.22%) (0.25%) (0.34%)
Oral Steroids 1 1 2 4 35 4 39 43
  (1.69%) (3.70%) (1.87%) (2.07%) (1.52%) (0.89%) (1.41%) (1.46%)
TB Case Contact 4 1 8 13 182 31 213 226
  (6.78%) (3.70%) (7.48%) (6.74%) (7.89%) (6.87%) (7.72%) (7.66%)
Total 6 5 16 27 312 48 360 387
Symptoms
Fatigue 0 1 6 7 43 8 51 58
  (0.00%) (3.70%) (5.61%) (3.63%) (1.86%) (1.77%) (1.85%) (1.97%)
Fever 0 0 2 2 3 1 4 6
  (0.00%) (0.00%) (1.87%) (1.04%) (0.13%) (0.22%) (0.15%) (0.20%)
Weight Loss 0 0 0 0 10 4 14 14
  (0.00%) (0.00%) (0.00%) (0.00%) (0.43%) (0.89%) (0.51%) (0.47%)
Loss of Appetite 0 0 1 1 4 2 6 7
  (0.00%) (0.00%) (0.93%) (0.52%) (0.17%) (0.44%) (0.22%) (0.24%)
Night Sweats 3 1 1 5 24 10 34 39
  (5.08%) (3.70%) (0.93%) (2.59%) (1.04%) (2.22%) (1.23 %) (1.32%)
Hoarseness 2 0 4 6 13 3 16 22
  (3.39%) (0.00%) (3.74%) (3.11%) (0.56%) (0.67%) (0.58%) (0.75%)
Productive Cough 8 0 0 8 34 15 49 57
  (13.56%) (0.00%) (0.00%) (4.15%) (1.47%) (3.33%) (1.78%) (1.93%)
Coughing Blood 0 0 0 0 3 1 4 4
  (0.00%) (0.00%) (0.00%) (0.00%) (0.13%) (0.22%) (0.15%) (0.14%)
Chest Pains 2 1 3 6 14 4 18 24
  (3.39%) (3.70%) (2.80%) (3.11%) (0.61%) (0.89%) (0.65%) (0.81%)
Total 15 3 17 35 148 48 196 231

 

Appendix G:
Inmate Populations 2005-2006

Table G.1: Federal Institutions in CSC and Inmate Populations 2005-2006

Institutions (by Region)
Level of 
security
Male Female General Population New Admissions
2005 2006 2005 2006

Source: Correctional Service of Canada, Performance Management, 2006.
1 – Recorded in OMS as a being admitted to CSC via a facility other than a federal institution
2 – Includes Millhaven Institution and those in Millhaven Assessment at the beginning of the year.

CSC Total - - - 12,222 13,280 4,798 5,057
Male - - - 11,835 12,835 4,530 4,757
Female - - - 387 445 268 300
Atlantic       1,168 1,292 575 573
Atlantic Institution Maximum   180 212 2 1
Dorchester Penitentiary Medium   345 400 0 0
Nova Institution for Women Multi-level   40 60 38 36
Springhill Institution Medium   379 393 424 433
Westmorland Institution Minimum   167 190 0 0
Other1       37 56 111 104
Quebec       3,033 3,283 1,055 965
Archambault Institution Medium   366 366 0 0
Cowansville Institution Medium   397 412 1 0
Donnacona Institution Maximum   265 306 0 0
Drummond Institution Medium   299 311 0 0
Federal Training Centre Minimum   214 204 0 0
Joliette Institution Multi-level   69 82 35 39
La Macaza Institution Medium   256 253 0 0
Leclerc Institution Medium   339 508 0 0
Montιe Saint-Franηois Institution Minimum   177 197 0 0
Port-Cartier Institution Maximum   177 182 0 0
Regional Reception Centre Maximum 263 242 1,018 926
Sainte-Anne-des-Plaines Minimum   131 138 0 0
Special Handling Unit Ultra Max   80 82 0 0
Other1       0 0 1 0
Ontario       3,191 3,592 1,316 1,379
Bath Institution Medium   313 320 0 0
Beaver Creek Institution Minimum   147 153 0 0
Collins Bay Institution Medium   223 234 0 0
Fenbrook Institution Medium   371 400 10 9
Frontenac Institution Minimum   128 172 0  
Grand Valley Institution for Women Multi-level   100 99 74 89
Isabel McNeill House Minimum   3 5 0 0
Joyceville Institution Medium   404 464 1 0
Kingston Penitentiary Maximum   334 333 0 2
Millhaven Institution2 Maximum   418 502 1,221 1,255
Pittsburgh Institution Minimum   182 190 0 0
Regional Treatment Centre Maximum   110 129 0 0
Warkworth Institution Medium   543 571 0 0
Other1       19 20 11 24
Prairie       2,900 3,139 1,348 1,557
Bowden Institution Med/Min   509 544 201 295
Drumheller Institution Med/Min   471 506 258 294
Edmonton Institution Maximum   208 231 39 36
Edmonton Institution for Women Multi-level   100 109 95 86
Grand Cache Institution Minimum   221 223 224 255
Grierson Centre Minimum   27 26 0 0
Okimaw Ohci Healing Lodge Med/Min   18 26 0 6
Pe Sakastew Centre Minimum   25 40 0 1
Regional Psychiatric Centre Multi-level 184 175 1 0
Riverbend Institution Minimum   80 75 0 0
Rockwood Institution Minimum   75 96 0 0
Saskatchewan Penitentiary Medium 355 390 242 263
Saskatchewan Penitentiary Maximum Unit Maximum   74 73 1 11
Stony Mountain Institution Medium   466 553 257 283
Other1       60 44 31 27
Pacific       1,779 1,974 504 583
Kwμkwθxwelhp Minimum   42 34 0 0
Ferndale Institution Minimum   127 127 0 0
Kent Institution Maximum   243 217 1 3
Matsqui Institution Medium   224 344 0 0
Mission Institution Medium   269 271 0 0
Mountain Institution Medium   442 442 0 0
Regional Health Centre Pacific Maximum   298 168 0 4
Regional Reception Assessment Ctr. Multi-level   4 92 479 535
William Head Institution Medium   122 120 0 0
Fraser Valley Institute for Women Multi-level   47 52 19 33
Other       8 107 6 8

 

Previous page | ToC